Details of Disease

General Information of Disease (ID: DISF7P24)

Disease Name	Head-neck squamous cell carcinoma
Synonyms	squamous cell carcinoma, head and neck; carcinoma of the head and neck; squamous cell carcinoma, head and neck, somatic; HNSCC; squamous cell carcinoma of head and neck; head and neck squamous cell carcinoma; craniocervical region squamous cell carcinoma; squamous cell carcinoma of the head and neck; SCCHN; squamous cell carcinomas of head and neck
Disease Class	2D60: Metastatic lymph node neoplasm
Definition	A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.
Disease Hierarchy	DISQVIFL: Squamous cell carcinoma DISOU1DS: Head and neck carcinoma DISF7P24: Head-neck squamous cell carcinoma
ICD Code	ICD-11 ICD-11: 2D60.0 ICD-10 ICD-10: C77.0
Disease Identifiers	MONDO ID MONDO_0010150 MESH ID D000077195 UMLS CUI C1168401 OMIM ID 275355 MedGen ID 257911 SNOMED CT ID 716659002

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Mulitkine	DMLHI93	Phase 3	NA	[1]
Ozuriftamab vedotin	DMOI00X	Phase 2	Antibody drug conjugate	[2]
SB 11285	DMZ9YWG	Phase 1	NA	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 368 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCB1	TT3OT40	Limited	Biomarker	[4]
ABCC2	TTFLHJV	Limited	Altered Expression	[5]
ABCG2	TTIMJ02	Limited	Altered Expression	[6]
AKT1	TTWTSCV	Limited	Biomarker	[7]
ALDH2	TTFLN4T	Limited	Altered Expression	[8]
ATG2B	TTG6KCU	Limited	Genetic Variation	[9]
BBC3	TT7JUKC	Limited	Biomarker	[10]
BSG	TT5UJWD	Limited	Biomarker	[11]
CCND1	TTFCJ7S	Limited	Altered Expression	[12]
CYP1A2	TTS1DTU	Limited	Genetic Variation	[13]
DKK3	TTY2ZV6	Limited	Biomarker	[14]
DYRK1A	TTSBVFO	Limited	Biomarker	[15]
EIF4E	TTZGCP6	Limited	Biomarker	[16]
ERBB4	TTWALCO	Limited	Biomarker	[17]
FAT1	TTGUJYV	Limited	Altered Expression	[18]
FHIT	TTMS54D	Limited	Biomarker	[19]
GPNMB	TT7315J	Limited	Altered Expression	[20]
HPGDS	TTCYE56	Limited	Altered Expression	[21]
IL1RAP	TTWS50K	Limited	Biomarker	[22]
ITGB1	TTBVIQC	Limited	Biomarker	[23]
KLF4	TTTI53X	Limited	Altered Expression	[24]
MCL1	TTL53M6	Limited	Altered Expression	[25]
MDM2	TT9TE0O	Limited	Altered Expression	[26]
MDM4	TT9OUDQ	Limited	Biomarker	[27]
MMP14	TTJ4QE7	Limited	Biomarker	[28]
NFE2L2	TTA6ZN2	Limited	Biomarker	[29]
NOTCH1	TTB1STW	Limited	Biomarker	[30]
PRKD1	TTSLUMT	Limited	Altered Expression	[31]
PTK2	TTON5IT	Limited	Altered Expression	[32]
RAD51	TTC0G1L	Limited	Biomarker	[33]
RRM2	TT1S4LJ	Limited	Biomarker	[34]
TGFBR1	TTP4520	Limited	Biomarker	[35]
TNFRSF10B	TTW20TU	Limited	Autosomal dominant	[36]
TNFRSF10B	TTW20TU	Limited	Altered Expression	[37]
CA9	TT2LVK8	Disputed	Biomarker	[38]
ACACB	TTY84UG	moderate	Biomarker	[39]
ADORA2A	TTM2AOE	moderate	Genetic Variation	[40]
ADORA2B	TTNE7KG	moderate	Biomarker	[41]
AGR2	TT9K86S	moderate	Biomarker	[42]
ANGPTL4	TTWALY5	moderate	Altered Expression	[43]
ARF1	TT70KXY	moderate	Altered Expression	[44]
ATF4	TTQCKWT	moderate	Biomarker	[45]
BCL2A1	TTGT9C7	moderate	Biomarker	[39]
BIRC2	TTQ5LRD	moderate	Biomarker	[46]
BRIP1	TTZV7LJ	moderate	Biomarker	[47]
BST2	TT90BJT	moderate	Biomarker	[48]
CBL	TT7QT13	moderate	Altered Expression	[49]
CBR1	TTVG0SN	moderate	Biomarker	[50]
CD200	TT0BE68	moderate	Altered Expression	[51]
CD276	TT6CQUM	moderate	Biomarker	[52]
CD33	TTJVYO3	moderate	Biomarker	[53]
CD70	TTNCIE0	moderate	Altered Expression	[54]
CDK6	TTO0FDJ	moderate	Biomarker	[55]
CDK7	TTQYF7G	moderate	Altered Expression	[56]
CEACAM1	TTA9CK4	moderate	Biomarker	[57]
CSE1L	TTTRULD	moderate	Biomarker	[58]
CTSH	TT3G406	moderate	Biomarker	[59]
CUL3	TTPCU0Q	moderate	Biomarker	[60]
DCLK1	TTOHTCY	moderate	Biomarker	[61]
DDX58	TTVB0O3	moderate	Biomarker	[62]
DIABLO	TTN74LE	moderate	Biomarker	[63]
DTL	TT8396I	moderate	Altered Expression	[64]
ECE1	TTQ9RYT	moderate	Biomarker	[65]
EIF4EBP1	TTKGEBL	moderate	Biomarker	[16]
ENTPD1	TTYM8DJ	moderate	Altered Expression	[66]
EPHA3	TTHS2LR	moderate	Biomarker	[67]
EPHB1	TT8MDAC	moderate	Biomarker	[68]
EREG	TTYSB89	moderate	Altered Expression	[69]
FANCA	TTV5HJS	moderate	Biomarker	[70]
FGF19	TTGCH11	moderate	Biomarker	[71]
FLT4	TTDCBX5	moderate	Altered Expression	[72]
FOLR2	TTT54CI	moderate	Biomarker	[73]
FTH1	TT975ZT	moderate	Altered Expression	[74]
GNG7	TTCMBKF	moderate	Posttranslational Modification	[75]
GNRHR	TT8R70G	moderate	Biomarker	[76]
GRK2	TTAZ3MN	moderate	Altered Expression	[77]
ID2	TTW8A5N	moderate	Altered Expression	[78]
IFNAR1	TTSYFMA	moderate	Altered Expression	[79]
IGFBP5	TTDWEA8	moderate	Genetic Variation	[80]
IL13RA2	TTMPZ7V	moderate	Biomarker	[81]
IL24	TT1EPXZ	moderate	Genetic Variation	[82]
ITGA11	TTANXZ7	moderate	Altered Expression	[83]
ITK	TT3C80U	moderate	Biomarker	[84]
KDM5B	TTCLI75	moderate	Altered Expression	[85]
KIR2DL2	TTU0P73	moderate	Genetic Variation	[86]
KLRK1	TTLRN4A	moderate	Biomarker	[87]
LAMB3	TT2WOUQ	moderate	Altered Expression	[88]
LAPTM4B	TTEJQT0	moderate	Altered Expression	[89]
LASP1	TTZJA87	moderate	Altered Expression	[90]
LTA	TTP73TM	moderate	Altered Expression	[91]
LTF	TTSZDQU	moderate	Biomarker	[92]
LYN	TT1RWNJ	moderate	Altered Expression	[53]
MAPK1	TT4TQBX	moderate	Altered Expression	[93]
MAPKAPK2	TTMUG9D	moderate	Biomarker	[94]
MLANA	TT362RB	moderate	Altered Expression	[95]
MVD	TTE5J6X	moderate	Biomarker	[96]
MYH2	TTBIL13	moderate	Biomarker	[97]
NEDD8	TTNDC4K	moderate	Biomarker	[98]
NEK2	TT3VZ24	moderate	Biomarker	[99]
NR1H2	TTXA6PH	moderate	Genetic Variation	[100]
NSD1	TTTSJ3H	moderate	Genetic Variation	[101]
NTSR1	TTTUMEP	moderate	Biomarker	[102]
OLFM4	TTK1CX7	moderate	Altered Expression	[103]
PFKFB3	TTTHMQJ	moderate	Altered Expression	[91]
PNP	TTMCF1Y	moderate	Biomarker	[104]
POLB	TTA0XPV	moderate	Altered Expression	[105]
PTK7	TTXH2ZN	moderate	Biomarker	[106]
PYGM	TTZHY6R	moderate	Biomarker	[107]
RHCG	TTN5MZ3	moderate	Biomarker	[108]
RICTOR	TT143WL	moderate	Altered Expression	[109]
RIPK1	TTVJHX8	moderate	Biomarker	[110]
SLC16A3	TTG6VD5	moderate	Altered Expression	[111]
SLC2A4	TTP6MT5	moderate	Biomarker	[112]
SLC38A2	TTUSC27	moderate	Altered Expression	[113]
SLC47A1	TTMHCGA	moderate	Biomarker	[114]
SLC7A11	TTBZMIO	moderate	Biomarker	[115]
SLC9A1	TTGSEFH	moderate	Altered Expression	[116]
SLCO1A2	TTUGD21	moderate	Altered Expression	[117]
SLCO1B3	TTU86P0	moderate	Altered Expression	[117]
SLCO2A1	TTKVTQO	moderate	Biomarker	[117]
SLCO2B1	TTDL3UZ	moderate	Altered Expression	[117]
SPOCK1	TTF23RE	moderate	Altered Expression	[118]
STOML2	TTOI329	moderate	Biomarker	[119]
TACSTD2	TTP2HE5	moderate	Biomarker	[120]
TGFB3	TTWOMY8	moderate	Biomarker	[121]
TIGIT	TTWNL74	moderate	Biomarker	[122]
TLR8	TT8CWFK	moderate	Biomarker	[123]
TMSB4X	TTMVAIU	moderate	Biomarker	[124]
TNFRSF4	TTL31H0	moderate	Genetic Variation	[125]
TNNC2	TTYUMF5	moderate	Biomarker	[107]
TP53BP1	TTX4UE9	moderate	Altered Expression	[126]
TRIP12	TTG2CRH	moderate	Altered Expression	[126]
ABCC1	TTOI92F	Strong	Altered Expression	[127]
ABCC3	TTVLG21	Strong	Biomarker	[117]
ADH7	TT3LE7P	Strong	Genetic Variation	[128]
AIMP2	TTXWHGF	Strong	Altered Expression	[93]
ANO1	TTOJI4S	Strong	Altered Expression	[129]
ANXA5	TT2Z83I	Strong	Biomarker	[130]
AREG	TT76B3W	Strong	Altered Expression	[69]
ARG2	TTV1AG6	Strong	Altered Expression	[131]
ATP2A2	TTE6THL	Strong	Genetic Variation	[132]
AURKA	TTPS3C0	Strong	Biomarker	[133]
AURKB	TT9RTBL	Strong	Biomarker	[134]
AVP	TTJ8EWH	Strong	Genetic Variation	[135]
AXL	TTZPY6J	Strong	Biomarker	[136]
AZGP1	TTUPYLV	Strong	Altered Expression	[137]
B2M	TTY7FKA	Strong	Genetic Variation	[138]
BUB1	TT78309	Strong	Genetic Variation	[139]
CALCR	TTLWS2O	Strong	Genetic Variation	[140]
CASP6	TTKW4ML	Strong	Genetic Variation	[141]
CASP7	TTM7Y45	Strong	Genetic Variation	[141]
CASP8	TT6SZNG	Strong	Genetic Variation	[142]
CCL23	TTHAPJK	Strong	Biomarker	[143]
CCR4	TT7HQD0	Strong	Altered Expression	[144]
CCR7	TT2GIDQ	Strong	Biomarker	[145]
CD163	TTTZ9DE	Strong	Biomarker	[146]
CD1A	TTBGTFN	Strong	Biomarker	[147]
CD274	TT8ZLTI	Strong	Altered Expression	[148]
CD46	TTMS7DF	Strong	Biomarker	[149]
CD47	TT28S46	Strong	Biomarker	[150]
CD69	TTPQE9F	Strong	Altered Expression	[151]
CD9	TTZEIBV	Strong	Altered Expression	[152]
CDC25A	TTLZS4Q	Strong	Biomarker	[153]
CDH11	TTRGWZC	Strong	Biomarker	[154]
CDK4	TT0PG8F	Strong	Biomarker	[155]
CDK9	TT1LVF2	Strong	Biomarker	[98]
CEACAM6	TTIGH2W	Strong	Altered Expression	[156]
CEBPA	TT5LWG1	Strong	Biomarker	[157]
COL1A2	TTUABC1	Strong	Altered Expression	[158]
CREBBP	TTFRCTK	Strong	Biomarker	[159]
CRK	TTFEUYR	Strong	Altered Expression	[93]
CSNK2A2	TT7GR5W	Strong	Biomarker	[160]
CSPG4	TT7MYXI	Strong	Altered Expression	[161]
CTCFL	TTY0RZT	Strong	Altered Expression	[162]
CTLA4	TTI2S1D	Strong	Biomarker	[163]
CXCL12	TT4UGTF	Strong	Biomarker	[158]
CYP1B1	TTI84H7	Strong	Genetic Variation	[164]
CYP26A1	TTD7Q0R	Strong	Altered Expression	[165]
CYP2E1	TTWVHQ5	Strong	Genetic Variation	[166]
CYP2J2	TTNE1C7	Strong	Altered Expression	[167]
DDC	TTN451K	Strong	Altered Expression	[168]
DDIT4	TTVEOY6	Strong	Altered Expression	[169]
DDR2	TTU98HG	Strong	Altered Expression	[170]
DDX5	TTZKPVC	Strong	Altered Expression	[171]
DEK	TT1NMGV	Strong	Altered Expression	[172]
DHCR24	TTTK0NH	Strong	Biomarker	[173]
DOT1L	TTSZ8T1	Strong	Altered Expression	[174]
DSG3	TTEO4P8	Strong	Altered Expression	[175]
DUSP5	TTZN92A	Strong	Biomarker	[134]
E2F1	TTASI04	Strong	Biomarker	[176]
E2F2	TT5FYX0	Strong	Genetic Variation	[176]
E2F3	TTWIJYH	Strong	Altered Expression	[177]
EBI3	TTJF68X	Strong	Altered Expression	[178]
EDNRB	TT3ZTGU	Strong	Biomarker	[179]
EGF	TTED8JB	Strong	Biomarker	[180]
EIF2AK2	TTXEZJ4	Strong	Biomarker	[181]
ELAVL1	TTPC9D0	Strong	Altered Expression	[182]
EP300	TTGH73N	Strong	Genetic Variation	[183]
EPCAM	TTZ8WH4	Strong	Altered Expression	[184]
EPHA1	TTLFZVU	Strong	Biomarker	[185]
EPHA2	TTRJB2G	Strong	Biomarker	[186]
EPHA8	TTHZ2LW	Strong	Altered Expression	[187]
EPHB3	TT5LM7U	Strong	Biomarker	[188]
EPHB4	TTI4ZX2	Strong	Altered Expression	[189]
ERBB3	TTSINU2	Strong	Biomarker	[190]
ETS1	TTTGPSD	Strong	Altered Expression	[191]
F11R	TT3C8EG	Strong	Biomarker	[192]
FCGR3A	TTIFOC0	Strong	Biomarker	[193]
FGF7	TTFY134	Strong	Biomarker	[194]
FGFR3	TTST7KB	Strong	Genetic Variation	[195]
FGFR4	TT1KX2S	Strong	Altered Expression	[187]
FHL1	TTI7ENL	Strong	Altered Expression	[196]
FOXM1	TTD3KOX	Strong	Altered Expression	[197]
GAL	TTXZAJ5	Strong	Biomarker	[198]
GALR1	TTX3HNZ	Strong	Biomarker	[199]
GALR2	TTBPW3J	Strong	Posttranslational Modification	[200]
GEM	TTAZF9M	Strong	Biomarker	[201]
GMNN	TT390KA	Strong	Biomarker	[33]
GRPR	TTC1MVT	Strong	Altered Expression	[202]
GSTO1	TTWO3SH	Strong	Genetic Variation	[203]
HDAC9	TT8M4E1	Strong	Biomarker	[204]
HDGF	TTKGV26	Strong	Biomarker	[205]
HMGA2	TTSTVM0	Strong	Altered Expression	[206]
HMGB2	TTA78JQ	Strong	Biomarker	[207]
HOXA5	TTXSVQP	Strong	Biomarker	[208]
HPSE	TTR7GJO	Strong	Biomarker	[209]
HSPB3	TTLH8WG	Strong	Altered Expression	[210]
IFNL3	TTRF4Q2	Strong	Therapeutic	[211]
IGF1	TTT6LOU	Strong	Biomarker	[212]
IGFBP3	TTZHNQA	Strong	Biomarker	[213]
IGFBP7	TTUQ01B	Strong	Altered Expression	[214]
IL1A	TTPM6HI	Strong	Altered Expression	[215]
IL4R	TTDWHC3	Strong	Biomarker	[216]
INHBA	TTVB30D	Strong	Biomarker	[217]
IRS1	TTAJSQ0	Strong	Biomarker	[212]
KCNH1	TT9XKUC	Strong	Biomarker	[218]
KIF11	TTBGTCW	Strong	Biomarker	[219]
KIR2DS1	TTVWAGF	Strong	Biomarker	[86]
KIR3DL2	TTQH3N0	Strong	Altered Expression	[201]
KISS1	TTU2O6T	Strong	Therapeutic	[220]
KLK8	TTH5MRS	Strong	Altered Expression	[221]
KNG1	TTDJ4MY	Strong	Biomarker	[222]
KRT17	TTKV0EC	Strong	Altered Expression	[223]
KRT19	TT3JF9E	Strong	Altered Expression	[224]
LAMP1	TTC214J	Strong	Altered Expression	[151]
LDHA	TTW76JE	Strong	Biomarker	[225]
LGALS1	TTO3NYT	Strong	Biomarker	[226]
LOXL2	TTFSUHX	Strong	Biomarker	[227]
LPAR4	TT7ZMY4	Strong	Altered Expression	[228]
LRP1	TTF2V7I	Strong	Biomarker	[229]
LTB	TTHQ6US	Strong	Genetic Variation	[230]
LY6D	TTINE9B	Strong	Altered Expression	[231]
LY6K	TT5GKHN	Strong	Biomarker	[232]
LYVE1	TTG8DNU	Strong	Biomarker	[233]
MAGEA1	TT63M7Q	Strong	Altered Expression	[234]
MAGEA3	TTWSKHD	Strong	Biomarker	[234]
MAP2K1	TTIDAPM	Strong	Biomarker	[235]
MAP2K2	TT8H9GB	Strong	Genetic Variation	[138]
MAP2K7	TT6QY3J	Strong	Biomarker	[236]
MAP3K8	TTGECUM	Strong	Genetic Variation	[237]
MAPK10	TT056SO	Strong	Altered Expression	[238]
MCM7	TT1RM3F	Strong	Biomarker	[239]
MELK	TTBZOTY	Strong	Biomarker	[240]
MERTK	TTO7LKR	Strong	Biomarker	[136]
MLH1	TTISG27	Strong	Posttranslational Modification	[241]
MMP1	TTMX39J	Strong	Biomarker	[242]
MMP10	TTXLEG7	Strong	Biomarker	[243]
MMP17	TTVSZKN	Strong	Altered Expression	[244]
MMP3	TTUZ2L5	Strong	Genetic Variation	[245]
MRC1	TTKV8W5	Strong	Biomarker	[246]
MSMB	TTYH1ZK	Strong	Posttranslational Modification	[247]
MTDH	TTH6SA5	Strong	Biomarker	[248]
MTR	TTUTO39	Strong	Genetic Variation	[249]
NAMPT	TTD1WIG	Strong	Biomarker	[250]
NCR1	TTQNRJM	Strong	Biomarker	[251]
NDUFA13	TTRU1NG	Strong	Posttranslational Modification	[252]
NEDD9	TT1UREA	Strong	Biomarker	[253]
NEK7	TTJ5SWP	Strong	Altered Expression	[254]
NGFR	TTEDJN4	Strong	Altered Expression	[255]
NLRX1	TTKT026	Strong	Biomarker	[256]
NME1	TTDY8JH	Strong	Altered Expression	[257]
NR1I2	TT7LCTF	Strong	Altered Expression	[258]
NR4A2	TT9HKN3	Strong	Biomarker	[259]
NT5E	TTK0O6Y	Strong	Biomarker	[260]
NUAK1	TT65FL0	Strong	Biomarker	[261]
OAT	TTTSCQ2	Strong	Biomarker	[131]
OGFR	TT6IEYX	Strong	Biomarker	[262]
OGG1	TTRU01G	Strong	Genetic Variation	[263]
P2RX1	TTJW7B3	Strong	Altered Expression	[264]
P2RX3	TT2THBD	Strong	Altered Expression	[264]
P2RX4	TT1NLOA	Strong	Altered Expression	[264]
P2RY1	TTA93TL	Strong	Altered Expression	[264]
P2RY2	TTOZHQC	Strong	Altered Expression	[264]
P4HA1	TTNH25W	Strong	Biomarker	[265]
PCSK7	TTD30LY	Strong	Altered Expression	[266]
PDCD1	TTNBFWK	Strong	Biomarker	[148]
PDCD1LG2	TTW14O3	Strong	Altered Expression	[267]
PDE5A	TTJ0IQB	Strong	Biomarker	[268]
PDK1	TTCZOF2	Strong	Biomarker	[30]
PECAM1	TT4EZB2	Strong	Biomarker	[91]
PIK3CA	TTEUNMR	Strong	Biomarker	[269]
PIK3CB	TT9H4P3	Strong	Biomarker	[269]
PIN1	TTJNTSI	Strong	Genetic Variation	[270]
PKN2	TTTHO0M	Strong	Biomarker	[271]
POSTN	TT8ALTZ	Strong	Biomarker	[158]
PRDX4	TTPBL9I	Strong	Biomarker	[272]
PRLR	TTBPXMA	Strong	Biomarker	[273]
PSMD10	TT2H4LN	Strong	Altered Expression	[274]
PTGER3	TTPNGDE	Strong	Altered Expression	[275]
PTGES	TTYLQ8V	Strong	Altered Expression	[276]
PTK2B	TTTEFBV	Strong	Biomarker	[225]
PTPN13	TT405FP	Strong	Biomarker	[277]
PTPRJ	TTWMKXP	Strong	Biomarker	[278]
RAC1	TT2M9CG	Strong	Genetic Variation	[138]
RACK1	TTJ10AL	Strong	Biomarker	[279]
RARG	TT1Q3IE	Strong	Altered Expression	[280]
REL	TT1ZCTH	Strong	Biomarker	[281]
RHOA	TTP2U16	Strong	Genetic Variation	[138]
RPE65	TTBOH16	Strong	Biomarker	[282]
RPS6KA3	TTUM2ZR	Strong	Biomarker	[210]
S100A4	TTPR5SX	Strong	Altered Expression	[283]
S100A8	TT4AF6N	Strong	Biomarker	[284]
SAA1	TTY0DN9	Strong	Altered Expression	[285]
SEMA4D	TT5UT28	Strong	Biomarker	[286]
SERPINB3	TT6QLPX	Strong	Biomarker	[287]
SERPINH1	TTPSWQG	Strong	Altered Expression	[288]
SLC1A5	TTF7WRM	Strong	Biomarker	[113]
SLC22A3	TTG2UMS	Strong	Biomarker	[84]
SLC3A2	TT5CZSM	Strong	Altered Expression	[289]
SLC6A8	TTYUHB5	Strong	Genetic Variation	[140]
SLC7A5	TTPH2JB	Strong	Altered Expression	[289]
SMYD2	TT7YJFO	Strong	Biomarker	[290]
SOCS3	TTI0ME6	Strong	Biomarker	[291]
SOD2	TT9O4C5	Strong	Altered Expression	[8]
SOX2	TTCNOT6	Strong	Biomarker	[240]
SPHK1	TTOHFIY	Strong	Biomarker	[292]
SRC	TT6PKBN	Strong	Altered Expression	[293]
SRPK2	TTCZEJ9	Strong	Biomarker	[294]
SSTR1	TTIND6G	Strong	Posttranslational Modification	[295]
STAT1	TTN7R6K	Strong	Biomarker	[296]
STC2	TT4EFTR	Strong	Altered Expression	[297]
STK17A	TTEYF03	Strong	Altered Expression	[298]
TAGLN2	TTP6BIJ	Strong	Biomarker	[299]
TFAP2A	TTDY4BS	Strong	Biomarker	[300]
TGFA	TTTLQFR	Strong	Genetic Variation	[301]
TKTL1	TTNQ1J3	Strong	Biomarker	[302]
TNFRSF10A	TT5WLRX	Strong	Biomarker	[303]
TPX2	TT0PHL4	Strong	Biomarker	[219]
TRIM24	TT9Q7AE	Strong	Altered Expression	[304]
TRPM3	TTO3TD8	Strong	Biomarker	[305]
TTK	TTP7EGM	Strong	Biomarker	[306]
TUSC2	TTJ8O14	Strong	Biomarker	[75]
TXNRD1	TTR7UJ3	Strong	Altered Expression	[229]
TYMS	TTP1UKZ	Strong	Biomarker	[307]
ULK1	TT4D7MJ	Strong	Altered Expression	[308]
UTRN	TTNO1VA	Strong	Altered Expression	[309]
VEGFC	TT0QUFV	Strong	Altered Expression	[310]
WEE1	TTJFOAL	Strong	Biomarker	[133]
WRN	TT2H5WQ	Strong	Biomarker	[311]
XPA	TTGT87E	Strong	Biomarker	[312]
XRCC5	TTCB9KW	Strong	Genetic Variation	[313]
YAP1	TT8UN2D	Strong	Altered Expression	[314]
ATP7B	TTOPO51	Definitive	Altered Expression	[315]
CCNA2	TTAMQ62	Definitive	Biomarker	[55]
CCNB1	TT9P6OW	Definitive	Biomarker	[55]
CCNE1	TTCEJ4F	Definitive	Biomarker	[55]
CCNE2	TTLDRGX	Definitive	Biomarker	[55]
FBXW7	TT29KY7	Definitive	Biomarker	[316]
------------------------------------------------------------------------------------


⏷ Show the Full List of 368 DTT(s)

This Disease Is Related to 3 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLCO6A1	DTIFXNS	Limited	Altered Expression	[317]
ABCC5	DTYVM24	moderate	Altered Expression	[5]
SLC25A16	DTNU9EW	Strong	Biomarker	[318]
------------------------------------------------------------------------------------

This Disease Is Related to 21 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ADH1B	DEEN9RD	Limited	Genetic Variation	[166]
AKR1C1	DE7P2FB	moderate	Biomarker	[319]
GLS	DE3E0VT	moderate	Altered Expression	[113]
ADH1C	DEM1HNL	Strong	Genetic Variation	[135]
AKR1A1	DED2FW3	Strong	Genetic Variation	[135]
ALDH1A1	DE2JP1Y	Strong	Biomarker	[320]
CRMP1	DE0EUXB	Strong	Altered Expression	[309]
CYP2A13	DEXZA9U	Strong	Genetic Variation	[321]
EGLN3	DEMQTKH	Strong	Altered Expression	[322]
EPHX1	DELB4KP	Strong	Genetic Variation	[321]
GGCT	DEKW6PB	Strong	Genetic Variation	[323]
GSTO2	DEHMPZR	Strong	Genetic Variation	[203]
HSD17B12	DE915QP	Strong	Biomarker	[324]
ME1	DE97WM8	Strong	Altered Expression	[325]
MTRR	DE6NIY9	Strong	Genetic Variation	[326]
NAT1	DE7OAB3	Strong	Genetic Variation	[327]
PER1	DE9HF0I	Strong	Altered Expression	[328]
SAT1	DEMWO83	Strong	Biomarker	[329]
SULT1A1	DEYWLRK	Strong	Genetic Variation	[330]
SULT1E1	DESTKG6	Strong	Genetic Variation	[237]
UPRT	DE20ETR	Strong	Biomarker	[331]
------------------------------------------------------------------------------------


⏷ Show the Full List of 21 DME(s)

This Disease Is Related to 480 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ING1	OTEZBRKW	No Known	Unknown	[36]
APOBEC3A	OTYO6F5P	Limited	Biomarker	[332]
ATG10	OTVRPC5X	Limited	Genetic Variation	[9]
CAPN6	OT8K5PR5	Limited	Biomarker	[333]
DCC	OT2C1SHW	Limited	Biomarker	[334]
DDB2	OTO8HVVB	Limited	Biomarker	[335]
DSC1	OTNII6GZ	Limited	Biomarker	[336]
E2F5	OT1XWING	Limited	Biomarker	[337]
ERCC5	OTQAKFJM	Limited	Genetic Variation	[338]
FJX1	OT8SVTSS	Limited	Biomarker	[339]
GNA13	OTVDL515	Limited	Biomarker	[340]
GSTK1	OTDNGWAF	Limited	Altered Expression	[317]
KLF6	OTQY9S7F	Limited	Biomarker	[341]
MAGED4B	OTO37U7W	Limited	Altered Expression	[339]
MAP3K13	OTS93BTX	Limited	Biomarker	[342]
MED15	OT0D0JVD	Limited	Biomarker	[343]
MTUS1	OTBPALMU	Limited	Biomarker	[344]
MVP	OTJGHJRB	Limited	Biomarker	[345]
NBN	OT73B5MD	Limited	Biomarker	[346]
NDRG1	OTVO66BO	Limited	Biomarker	[347]
NMU	OTW9X7BQ	Limited	Biomarker	[348]
PSD4	OTEFB87Z	Limited	Biomarker	[340]
RPA3	OT8JAQGL	Limited	Altered Expression	[349]
RPL14	OTZZW7TK	Limited	Genetic Variation	[350]
S100A2	OTTGHJ1H	Limited	Altered Expression	[351]
SERPINA5	OTTZXPGD	Limited	Biomarker	[352]
SGSM3	OTIB1P8A	Limited	Genetic Variation	[353]
SLPI	OTUNFUU8	Limited	Altered Expression	[354]
TBX3	OTM64N7K	Limited	Altered Expression	[355]
TCHP	OTVDMHSY	Limited	Biomarker	[333]
TNFRSF10B	OTA1CPBV	Limited	Autosomal dominant	[36]
TSC2	OT47LWI9	Limited	Altered Expression	[356]
ACTA1	OTOVGLPG	moderate	Biomarker	[357]
ACTL6A	OT0EC5BQ	moderate	Biomarker	[282]
ACTL8	OTUDD0QT	moderate	Altered Expression	[352]
AFF4	OTTL5Y8R	moderate	Biomarker	[358]
AJUBA	OTNW7YPK	moderate	Genetic Variation	[359]
ALDH3A1	OTAYZZE6	moderate	Altered Expression	[360]
ALG3	OTPOL1QW	moderate	Altered Expression	[361]
AP1G1	OTEO6Y9H	moderate	Biomarker	[362]
ATG12	OTJRO09Y	moderate	Genetic Variation	[363]
ATG16L1	OTEOYC5D	moderate	Genetic Variation	[363]
BCL10	OT47MCLI	moderate	Altered Expression	[364]
CCL15	OTOGZ85M	moderate	Altered Expression	[365]
CCL18	OT7JYSK9	moderate	Altered Expression	[366]
CD247	OT45FGUX	moderate	Altered Expression	[367]
CMAS	OTFQJG3C	moderate	Biomarker	[368]
COX3	OTNNGBYJ	moderate	Biomarker	[369]
CPEB4	OTW1SCZW	moderate	Altered Expression	[370]
CTNND1	OTUMPSHR	moderate	Biomarker	[58]
CUL4B	OT2QX4DO	moderate	Altered Expression	[371]
CYTB	OTAHB98A	moderate	Altered Expression	[369]
DDB1	OTTR2L3Z	moderate	Altered Expression	[372]
DDX3X	OTDO4TRX	moderate	Biomarker	[373]
DERL1	OTJUS74N	moderate	Altered Expression	[374]
DIAPH1	OTZBYPLH	moderate	Altered Expression	[375]
DNAJB7	OT4BOECZ	moderate	Biomarker	[376]
DOCK5	OT63I0CL	moderate	Altered Expression	[377]
DSPP	OT1TYNDN	moderate	Biomarker	[378]
DTX1	OTYX91DX	moderate	Altered Expression	[379]
DUOX1	OTQ2AEW0	moderate	Biomarker	[380]
EIF3A	OTFABY9G	moderate	Biomarker	[373]
ELMO3	OTQHO9VM	moderate	Altered Expression	[381]
ERCC3	OTVAW3P1	moderate	Altered Expression	[100]
FAM135B	OTCSYBI7	moderate	Biomarker	[382]
FANCD2	OTVEB5LF	moderate	Biomarker	[383]
FBXO4	OT6VYX67	moderate	Biomarker	[384]
FCGBP	OT63T6XQ	moderate	Altered Expression	[385]
FTL	OTYQA8A6	moderate	Altered Expression	[74]
FXR1	OTEMQ1SR	moderate	Biomarker	[384]
GAGE1	OT53E50E	moderate	Biomarker	[386]
GCC1	OTDOE6U8	moderate	Altered Expression	[387]
GPRC5A	OTPOCWR7	moderate	Altered Expression	[388]
GRAP	OTO1P7YX	moderate	Biomarker	[389]
GRP	OT8JDFNI	moderate	Biomarker	[31]
GTF2H1	OTCRXC6B	moderate	Altered Expression	[390]
GTF2H2	OTK72L9I	moderate	Altered Expression	[390]
GTF2H3	OT87W5QJ	moderate	Altered Expression	[390]
GTF2H4	OTPD1DIU	moderate	Altered Expression	[390]
GTF2H5	OTRL219S	moderate	Altered Expression	[390]
HNRNPC	OT47AK4C	moderate	Biomarker	[391]
HOPX	OTBSR6C9	moderate	Biomarker	[392]
HOXA10	OTB6GQ09	moderate	Altered Expression	[393]
HOXA9	OTKNK5H0	moderate	Biomarker	[394]
IL17B	OTS86H50	moderate	Biomarker	[395]
IL17RA	OTVVI8ER	moderate	Biomarker	[396]
IRX1	OT0ZN9EJ	moderate	Biomarker	[397]
JMJD6	OTILR7E4	moderate	Altered Expression	[398]
JMJD7-PLA2G4B	OTXIGTKQ	moderate	Biomarker	[399]
JUNB	OTG2JXV5	moderate	Genetic Variation	[80]
JUND	OTNKACJD	moderate	Genetic Variation	[80]
KIR2DL5A	OT09FZE1	moderate	Biomarker	[86]
KIR2DL5B	OTSV0JL9	moderate	Biomarker	[86]
KIR2DS4	OT00N6UJ	moderate	Genetic Variation	[86]
LAT	OTZC1XZ1	moderate	Altered Expression	[289]
LGALS9	OT7MF91K	moderate	Biomarker	[35]
LRG1	OTLD0KWA	moderate	Altered Expression	[400]
LRPPRC	OTXSK5LP	moderate	Biomarker	[401]
MAGEA11	OTLT6Q3G	moderate	Altered Expression	[386]
MAML1	OTQA4DDN	moderate	Altered Expression	[402]
NCOR2	OTY917X0	moderate	Altered Expression	[258]
NEURL1	OT2C4P70	moderate	Biomarker	[403]
NFYA	OTWFFOVH	moderate	Biomarker	[404]
NIPBL	OTF6OOLU	moderate	Biomarker	[405]
NSUN2	OTZCNM33	moderate	Genetic Variation	[406]
PDHA1	OTGEU8IK	moderate	Biomarker	[225]
PDLIM7	OTAZVODU	moderate	Biomarker	[407]
PFN2	OT5SSSA7	moderate	Altered Expression	[408]
PLAAT4	OTI66SAJ	moderate	Altered Expression	[62]
PLXNB1	OTCA7JIT	moderate	Biomarker	[286]
POPDC3	OTN4FJ5J	moderate	Biomarker	[409]
PTX3	OTPXHRKU	moderate	Biomarker	[410]
PWP1	OTUKXP1E	moderate	Altered Expression	[390]
QKI	OTTAUGLB	moderate	Altered Expression	[411]
RAB25	OTW0W6NP	moderate	Altered Expression	[412]
RABGEF1	OTWC3Z3R	moderate	Biomarker	[413]
RAP1A	OT5RH6TI	moderate	Biomarker	[413]
RBL2	OTBQSOE6	moderate	Genetic Variation	[414]
REG3G	OTLIUY8Z	moderate	Altered Expression	[415]
RFPL1	OTNQIVOJ	moderate	Biomarker	[416]
RHPN1	OTYZ1NV8	moderate	Biomarker	[417]
ROBO3	OTPVG40S	moderate	Biomarker	[62]
RPL17	OTTYMPS6	moderate	Biomarker	[418]
SEPTIN9	OT1VMRFQ	moderate	Biomarker	[419]
SERPINE2	OTYF5340	moderate	Genetic Variation	[420]
SESN2	OT889IXY	moderate	Altered Expression	[421]
SIGLEC1	OTNWSQA9	moderate	Altered Expression	[422]
SLC16A4	OT1YXBKC	moderate	Altered Expression	[111]
SLFN11	OTJWFPMY	moderate	Altered Expression	[67]
SLN	OTERIU75	moderate	Biomarker	[423]
SMARCD1	OTHFFT6G	moderate	Altered Expression	[424]
SNX5	OT6ZOWMU	moderate	Altered Expression	[316]
SPRR2A	OT62ZU6B	moderate	Biomarker	[425]
SRI	OT4R3EAC	moderate	Altered Expression	[426]
STAMBP	OTOT2OXM	moderate	Altered Expression	[427]
STING1	OTDAP4G0	moderate	Altered Expression	[428]
TAT	OT2CJ91O	moderate	Biomarker	[28]
TEAD4	OTJS0T2B	moderate	Biomarker	[429]
TENM2	OTPLUYEF	moderate	Biomarker	[430]
TERF2IP	OT3M5P3G	moderate	Biomarker	[413]
TIMM8A	OTDX9687	moderate	Biomarker	[431]
TLCD3B	OTM6EPUS	moderate	Biomarker	[432]
TMEM237	OTQEVL7L	moderate	Biomarker	[387]
TRAF2	OT1MEZZN	moderate	Biomarker	[433]
TRAF3	OT5TQBGV	moderate	Genetic Variation	[434]
ACOT7	OT7C68YV	Strong	Altered Expression	[435]
ACTBL2	OTD6B81U	Strong	Altered Expression	[435]
ACTG2	OTRDWUO0	Strong	Altered Expression	[435]
ADAM12	OTZKOTDB	Strong	Biomarker	[436]
AHSA1	OTC7AFHT	Strong	Altered Expression	[93]
ALKBH3	OTS1CD9Z	Strong	Altered Expression	[437]
ANKRD36B	OT3MW415	Strong	Altered Expression	[438]
ANXA6	OT9KIQ0Y	Strong	Altered Expression	[171]
APOBEC3B	OTHLNI51	Strong	Altered Expression	[439]
ARF6	OTVV7KJO	Strong	Altered Expression	[440]
ARHGAP1	OT0H2ZBZ	Strong	Altered Expression	[441]
ARHGAP21	OT6XY8Y9	Strong	Altered Expression	[441]
ARHGAP24	OTCQCEZS	Strong	Genetic Variation	[442]
ARHGEF28	OT3F32IU	Strong	Altered Expression	[443]
ARID2	OTIRJXWM	Strong	Biomarker	[305]
ARPC5	OTFNMMDL	Strong	Altered Expression	[444]
ASAP1	OT4DLRYY	Strong	Altered Expression	[440]
ASCC1	OTH4VAP9	Strong	Biomarker	[445]
ATF2	OTNIZPEA	Strong	Biomarker	[446]
ATP2A3	OTFYDEES	Strong	Genetic Variation	[132]
ATP5F1A	OT3FZDLX	Strong	Altered Expression	[447]
ATP5MC1	OTOLSYOI	Strong	Altered Expression	[447]
ATP5MC2	OTA5F480	Strong	Altered Expression	[447]
ATP5PF	OTDAE8FP	Strong	Altered Expression	[447]
AZIN2	OT8OB7CG	Strong	Biomarker	[448]
BCL11B	OT8KKCVJ	Strong	Altered Expression	[449]
BCL2L12	OTS6IFZY	Strong	Altered Expression	[450]
BHLHE40	OTITX14U	Strong	Genetic Variation	[451]
BHMT	OTYB6PXZ	Strong	Genetic Variation	[249]
BPNT1	OTPX5PSQ	Strong	Biomarker	[239]
C1GALT1	OT2ZSZ6P	Strong	Altered Expression	[452]
CANX	OTYP1F6J	Strong	Biomarker	[210]
CCDC54	OTW5WCX9	Strong	Altered Expression	[453]
CCDC8	OTO295IH	Strong	Biomarker	[210]
CCNA1	OTX4HD45	Strong	Biomarker	[55]
CCNL1	OTAJSS3D	Strong	Genetic Variation	[454]
CD151	OTF3UZS7	Strong	Altered Expression	[455]
CD68	OTOYEY3J	Strong	Biomarker	[146]
CDX1	OTOHTMJE	Strong	Altered Expression	[456]
CENPF	OT7AG0SW	Strong	Biomarker	[457]
CEP55	OTGSG2PA	Strong	Altered Expression	[458]
CERS1	OT6EYRM3	Strong	Altered Expression	[459]
CERS6	OTOP4GV1	Strong	Biomarker	[460]
CHAC1	OTJGE772	Strong	Altered Expression	[461]
CHD5	OTS5EVHH	Strong	Biomarker	[462]
CHP1	OTHTXN1A	Strong	Genetic Variation	[463]
CIP2A	OTVS2GXA	Strong	Biomarker	[464]
CKAP4	OTDUC9ME	Strong	Biomarker	[282]
CKMT1A	OTCINHH5	Strong	Altered Expression	[465]
CLOCK	OTNEOJY7	Strong	Altered Expression	[466]
CLPTM1L	OTDJWQXI	Strong	Genetic Variation	[467]
CLUH	OTCDYPZV	Strong	Genetic Variation	[468]
CMTM6	OT70T27A	Strong	Altered Expression	[469]
COL5A1	OT24078H	Strong	Biomarker	[239]
COMMD1	OT7WUD5R	Strong	Altered Expression	[470]
COMMD6	OTRZQJFW	Strong	Biomarker	[456]
COX2	OTTMVBJJ	Strong	Biomarker	[471]
COX5B	OTDP94F3	Strong	Biomarker	[472]
CRABP1	OTISDG5X	Strong	Altered Expression	[165]
CRABP2	OTY01V9G	Strong	Posttranslational Modification	[473]
CRTAP	OT53H5U6	Strong	Genetic Variation	[141]
CSH1	OT33HTRR	Strong	Biomarker	[474]
CSH2	OTW8JVAN	Strong	Biomarker	[474]
CSMD1	OTIVDSC4	Strong	Biomarker	[475]
CST2	OTRKRW50	Strong	Biomarker	[476]
CST5	OTHJXNJG	Strong	Biomarker	[476]
CST6	OTZVHJTF	Strong	Biomarker	[476]
CSTA	OT1K68KE	Strong	Biomarker	[476]
CT55	OTQC0H27	Strong	Altered Expression	[234]
CTDSPL	OTZJ0CZK	Strong	Genetic Variation	[477]
CTNNA2	OTJ8G92T	Strong	Biomarker	[478]
CTNNAL1	OTESJ6JD	Strong	Biomarker	[443]
CTTN	OTJRG4ES	Strong	Altered Expression	[479]
CXADR	OT9ZP02A	Strong	Altered Expression	[480]
CYGB	OTX153DQ	Strong	Posttranslational Modification	[481]
CYTIP	OTRJ3ZC5	Strong	Genetic Variation	[141]
DAPK1	OTNCNUCO	Strong	Altered Expression	[482]
DAPK2	OTWODUQG	Strong	Altered Expression	[309]
DCTN3	OTQOSUES	Strong	Genetic Variation	[463]
DCUN1D1	OT8UJLZU	Strong	Biomarker	[19]
DEFB103B	OT8RWY64	Strong	Altered Expression	[483]
DENR	OTXP9HOY	Strong	Altered Expression	[309]
DLAT	OT9LBJVN	Strong	Biomarker	[484]
DLC1	OTP8LMCR	Strong	Genetic Variation	[485]
DLEC1	OTMKKBUW	Strong	Posttranslational Modification	[486]
DNAJA3	OT61924T	Strong	Biomarker	[487]
DNAJC2	OT3JDA0R	Strong	Genetic Variation	[488]
DNER	OT2GH2E5	Strong	Biomarker	[489]
DPPA4	OTAEOACS	Strong	Biomarker	[490]
DST	OTHZBM4X	Strong	Biomarker	[491]
DUSP4	OT6WAO12	Strong	Biomarker	[492]
DYNC1H1	OTD1KRKO	Strong	Genetic Variation	[463]
E2F7	OTWW358N	Strong	Biomarker	[292]
ECT2	OTQDUCT6	Strong	Biomarker	[493]
EFNB2	OT0DCUOM	Strong	Biomarker	[189]
ELAVL2	OT6EJ8MQ	Strong	Altered Expression	[99]
ELF3	OTUTLEQO	Strong	Biomarker	[494]
ERCC4	OTFIOPG1	Strong	Altered Expression	[312]
ERCC6	OT2QZKSF	Strong	Biomarker	[474]
ESM1	OT331Y8V	Strong	Altered Expression	[495]
EXT1	OTRPALJK	Strong	Biomarker	[493]
FADD	OTV7GFHH	Strong	Genetic Variation	[496]
FANCC	OTTIDM3P	Strong	Biomarker	[497]
FANCE	OTKRPBW1	Strong	Biomarker	[498]
FANCL	OTJC7QPQ	Strong	Biomarker	[498]
FARP2	OTNRQIMK	Strong	Biomarker	[499]
FBLIM1	OTFHXMON	Strong	Biomarker	[500]
FEV	OTYEC4IR	Strong	Biomarker	[501]
FGF3	OT9PK2SI	Strong	Biomarker	[502]
FHL5	OT6C00Z1	Strong	Altered Expression	[435]
FLOT2	OTZ0QR5L	Strong	Biomarker	[503]
FSD1	OT8P6PT3	Strong	Biomarker	[504]
FSD1L	OTBQ48RF	Strong	Biomarker	[504]
FUT1	OTODG57A	Strong	Genetic Variation	[505]
FZR1	OT0WGWZS	Strong	Altered Expression	[506]
GAB1	OTQKE6V4	Strong	Biomarker	[507]
GADL1	OTJM4A0R	Strong	Biomarker	[448]
GATAD2B	OTJL128N	Strong	Altered Expression	[171]
GDF1	OTZ1VRBH	Strong	Altered Expression	[459]
GEMIN2	OT4L6TLL	Strong	Biomarker	[506]
GNAS	OTMH8BKJ	Strong	Genetic Variation	[138]
GNB3	OTA6HYBA	Strong	Genetic Variation	[508]
GOPC	OTRBGH71	Strong	Biomarker	[500]
GPAA1	OTWVRR35	Strong	Biomarker	[509]
GPD1L	OTVLWW9T	Strong	Altered Expression	[510]
GPR4	OTIBF32I	Strong	Biomarker	[511]
GRAP2	OTS5NIZ3	Strong	Altered Expression	[93]
GSTM2	OTG4WT05	Strong	Genetic Variation	[512]
GZMM	OTEC5CWT	Strong	Biomarker	[351]
HAVCR2	OTOL603T	Strong	Altered Expression	[513]
HCFC1R1	OTGDPS5C	Strong	Biomarker	[514]
HELLS	OTVVV668	Strong	Altered Expression	[515]
HELQ	OTL1STJT	Strong	Biomarker	[516]
HNRNPK	OTNPRM8U	Strong	Altered Expression	[517]
HNRNPL	OT0DJX74	Strong	Biomarker	[518]
HOXB9	OTMVHQOU	Strong	Altered Expression	[519]
HOXC6	OTBCRAZV	Strong	Altered Expression	[520]
HOXD11	OT9XGA4G	Strong	Biomarker	[208]
HRG	OTPLUFOG	Strong	Altered Expression	[521]
HSF2	OTXNJIJ9	Strong	Genetic Variation	[522]
HSPB2	OTS01646	Strong	Altered Expression	[210]
HUWE1	OTFH6BJS	Strong	Altered Expression	[523]
HYAL1	OT2SJN0X	Strong	Altered Expression	[524]
IDH2	OTTQA4PB	Strong	Genetic Variation	[138]
IFI16	OT4SPU0U	Strong	Biomarker	[525]
IL18R1	OT83XMPQ	Strong	Altered Expression	[178]
ING2	OT6H0EWF	Strong	Biomarker	[526]
ING3	OTDIJXFP	Strong	Altered Expression	[527]
ING4	OT0VVG4V	Strong	Biomarker	[528]
INTS2	OT2N5TCK	Strong	Biomarker	[502]
IRF6	OTKJ44EV	Strong	Biomarker	[529]
ISYNA1	OT49ONSE	Strong	Altered Expression	[530]
ITGA3	OTBCH21D	Strong	Altered Expression	[531]
ITGA9	OTHN1IKA	Strong	Genetic Variation	[477]
ITGB4	OT28UK84	Strong	Altered Expression	[532]
IVL	OT4VPNGY	Strong	Biomarker	[515]
KIF1A	OT3JVEGV	Strong	Biomarker	[533]
KIF22	OTY6X6BL	Strong	Biomarker	[534]
KIR3DL1	OTPOSXFX	Strong	Biomarker	[201]
KRT13	OTTYSKGX	Strong	Altered Expression	[223]
KRT16	OTGA0EQN	Strong	Altered Expression	[535]
KRT18	OTVLQFIP	Strong	Altered Expression	[536]
KRT5	OTVGI9HT	Strong	Biomarker	[537]
LAMA3	OTFME7HT	Strong	Biomarker	[491]
LATS1	OTOOCG4R	Strong	Posttranslational Modification	[538]
LDOC1	OTWZH4O9	Strong	Altered Expression	[539]
LGALS7	OTMSVI7R	Strong	Altered Expression	[487]
LHX6	OT47UQZ5	Strong	Biomarker	[397]
LIMD1	OTN1CG6R	Strong	Altered Expression	[540]
LMLN	OTQF0JPY	Strong	Posttranslational Modification	[247]
LOXL4	OT6XY2JL	Strong	Altered Expression	[541]
MAGEB2	OTAGUVU5	Strong	Biomarker	[542]
MAGEB6	OTOTV1FU	Strong	Genetic Variation	[234]
MAK16	OTD546E5	Strong	Biomarker	[543]
MAL	OTBM30SW	Strong	Biomarker	[533]
MARCHF8	OTH7PNN2	Strong	Biomarker	[544]
MAU2	OTALDF8Q	Strong	Biomarker	[545]
MFAP2	OTMHVBTV	Strong	Altered Expression	[546]
MICA	OTPEIEAR	Strong	Altered Expression	[547]
MICU1	OTS7N0LE	Strong	Altered Expression	[548]
MLXIP	OT30UNI7	Strong	Biomarker	[544]
MPEG1	OT7DAO0F	Strong	Biomarker	[306]
MRPL28	OT4LUTZU	Strong	Posttranslational Modification	[549]
MRPL41	OTG5URO4	Strong	Genetic Variation	[550]
MSN	OTZJ4J6G	Strong	Biomarker	[551]
MTHFD1	OTMKHVWC	Strong	Genetic Variation	[249]
MXI1	OTUQ9E0D	Strong	Biomarker	[552]
MYBBP1A	OTIVEMIU	Strong	Biomarker	[553]
MYCBPAP	OT3W21WR	Strong	Altered Expression	[440]
MYLIP	OTL0PFGV	Strong	Biomarker	[544]
MYO1B	OTGZUJ0I	Strong	Biomarker	[554]
NAA25	OTS3QVF1	Strong	Genetic Variation	[516]
NAB2	OTG4BDF3	Strong	Altered Expression	[180]
NANS	OTMQ2FUH	Strong	Altered Expression	[116]
NCBP2	OTQNZTE4	Strong	Biomarker	[493]
NCOA1	OTLIUJQD	Strong	Altered Expression	[465]
NDN	OTYBYJ82	Strong	Posttranslational Modification	[147]
NEIL1	OTHBU5DJ	Strong	Posttranslational Modification	[555]
NEUROD1	OTZQ7QJ2	Strong	Posttranslational Modification	[556]
NINL	OTWIK6HT	Strong	Altered Expression	[557]
NLRP2	OTJA81JU	Strong	Biomarker	[346]
NOL4	OTWI587R	Strong	Biomarker	[397]
NOVA1	OT6A9KHY	Strong	Biomarker	[558]
NSD2	OTQ6SW4R	Strong	Biomarker	[254]
NSD3	OT3677ZG	Strong	Biomarker	[559]
NSDHL	OTK3EJFD	Strong	Biomarker	[560]
NTNG1	OTF48IID	Strong	Biomarker	[561]
NXF1	OTEFHXG6	Strong	Biomarker	[547]
NXT1	OT0VO6AY	Strong	Posttranslational Modification	[549]
OBP2A	OTBIJ5TI	Strong	Biomarker	[534]
OR10A4	OTYYB8SY	Strong	Genetic Variation	[562]
OR2AG1	OTEITRP4	Strong	Biomarker	[563]
OXA1L	OTS0BFRD	Strong	Biomarker	[564]
P2RX2	OT0LF34A	Strong	Altered Expression	[264]
P2RX5	OTLBR20R	Strong	Altered Expression	[264]
P2RX6	OT1FNTXA	Strong	Altered Expression	[264]
PBXIP1	OTEAAUBY	Strong	Biomarker	[514]
PCDH18	OTTLQWRN	Strong	Biomarker	[565]
PDCD4	OTZ6NXUX	Strong	Altered Expression	[566]
PDPN	OTBUV19I	Strong	Altered Expression	[567]
PER3	OTVKYVJA	Strong	Altered Expression	[568]
PHB2	OTCAX3AW	Strong	Genetic Variation	[463]
PHF2	OTJCIQR2	Strong	Biomarker	[569]
PITX2	OTWMXAOY	Strong	Posttranslational Modification	[570]
PIWIL1	OT7CRGZ3	Strong	Altered Expression	[571]
PIWIL4	OTDA9MY0	Strong	Altered Expression	[571]
PLAGL1	OTZAO900	Strong	Biomarker	[572]
PLCE1	OTJISZOX	Strong	Genetic Variation	[573]
PLEC	OTU4XDEG	Strong	Biomarker	[574]
PMAIP1	OTXEE550	Strong	Altered Expression	[575]
PMPCB	OTRMBHNM	Strong	Genetic Variation	[488]
PNO1	OT010GIS	Strong	Biomarker	[543]
POLD1	OTWO4UCJ	Strong	Altered Expression	[576]
POLD3	OTEQEFQ2	Strong	Altered Expression	[171]
POLDIP2	OT8SZSJ6	Strong	Altered Expression	[93]
POTEM	OT7L2HGH	Strong	Altered Expression	[435]
PPFIA1	OTYYFA9C	Strong	Altered Expression	[361]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[138]
PRDM9	OTWAHLUR	Strong	Genetic Variation	[142]
PRIMA1	OT9ITT3P	Strong	Biomarker	[577]
PRRX1	OTTZK5G8	Strong	Biomarker	[93]
PTPA	OTRGFOI7	Strong	Biomarker	[578]
PTPRK	OTAP5AT3	Strong	Genetic Variation	[579]
PTPRT	OTV5TXNN	Strong	Biomarker	[580]
PTTG1IP	OTX21QTE	Strong	Biomarker	[581]
PUF60	OTG90DYF	Strong	Biomarker	[499]
PXN	OTVMMUOF	Strong	Biomarker	[306]
RAB40B	OTCA9ZF5	Strong	Biomarker	[582]
RACGAP1	OTQE8IEH	Strong	Altered Expression	[583]
RAD17	OT1I93DT	Strong	Altered Expression	[584]
RAD21	OTQS84ZF	Strong	Biomarker	[278]
RAD50	OTYMU9G1	Strong	Genetic Variation	[585]
RAD51C	OTUD6SY5	Strong	Genetic Variation	[586]
RAP1GAP	OTC31ONQ	Strong	Biomarker	[587]
RASSF1	OTEZIPB7	Strong	Posttranslational Modification	[588]
RASSF3	OT4V9SRK	Strong	Genetic Variation	[589]
RBMS3	OTFSC9MR	Strong	Biomarker	[543]
RBP2	OTR8QG5V	Strong	Biomarker	[590]
RBP3	OTIWM4GT	Strong	Biomarker	[591]
RBX1	OTYA1UIO	Strong	Biomarker	[592]
RCHY1	OTAE7504	Strong	Altered Expression	[593]
RECQL	OTPCH3JH	Strong	Biomarker	[311]
REV3L	OT0OP8EJ	Strong	Posttranslational Modification	[594]
RFC1	OT3L5PK3	Strong	Genetic Variation	[249]
RHOBTB2	OT2DATFX	Strong	Altered Expression	[595]
RHOC	OTOLE1FT	Strong	Altered Expression	[596]
RITA1	OTUH8IPS	Strong	Biomarker	[597]
RNF19A	OTKWCV80	Strong	Altered Expression	[93]
RPS27	OTFXKY7P	Strong	Biomarker	[306]
RPS29	OTCC1872	Strong	Altered Expression	[598]
RRM2B	OTE8GBUR	Strong	Genetic Variation	[599]
RYR2	OT0PF19E	Strong	Genetic Variation	[600]
S100A7	OTJFVJRF	Strong	Biomarker	[601]
SATB2	OT2W80XC	Strong	Biomarker	[602]
SBF1	OTW6I9RV	Strong	Biomarker	[603]
SCAF11	OTX59D0X	Strong	Biomarker	[506]
SCYL1	OTQ0IN7P	Strong	Biomarker	[604]
SDCBP	OTS3NCC5	Strong	Biomarker	[605]
SDCCAG8	OTV2ZGV9	Strong	Biomarker	[431]
SEC62	OTCWEL5F	Strong	Biomarker	[606]
SEPTIN4	OTD16B30	Strong	Biomarker	[607]
SERPINB13	OTILBHCE	Strong	Altered Expression	[608]
SERPINB2	OT72QLZB	Strong	Biomarker	[609]
SERPINB4	OT88LHZ8	Strong	Altered Expression	[610]
SERTAD1	OTBHKZQP	Strong	Biomarker	[274]
SET	OTGYYQJO	Strong	Altered Expression	[578]
SFN	OTLJCZ1U	Strong	Biomarker	[279]
SH3BP4	OTVIRKW7	Strong	Altered Expression	[611]
SH3GL2	OTOE443G	Strong	Biomarker	[612]
SH3KBP1	OTIUA60B	Strong	Biomarker	[613]
SHMT1	OTIINA3J	Strong	Genetic Variation	[249]
SHMT2	OT5NCAZN	Strong	Genetic Variation	[249]
SIRT4	OT5S0J23	Strong	Biomarker	[344]
SIRT7	OT5M4OT4	Strong	Biomarker	[614]
SMAD4	OTWQWCKG	Strong	Biomarker	[615]
SMARCA2	OTSGJ8SV	Strong	Genetic Variation	[616]
SMG1	OTTS3SXE	Strong	Altered Expression	[617]
SMR3A	OT6NAJJI	Strong	Altered Expression	[618]
SMUG1	OT2YIOCQ	Strong	Biomarker	[619]
SMURF1	OT5UIZR8	Strong	Altered Expression	[620]
SNAI2	OT7Y8EJ2	Strong	Biomarker	[621]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[622]
SPA17	OT8J7T7U	Strong	Altered Expression	[453]
SPATA2	OTOA45GL	Strong	Biomarker	[418]
SPTLC3	OTZDX6PT	Strong	Altered Expression	[623]
SRRM2	OTSIMMC9	Strong	Biomarker	[543]
SRSF3	OTOFT707	Strong	Biomarker	[518]
SUB1	OTK71JYU	Strong	Posttranslational Modification	[549]
SULF1	OTJCNCO0	Strong	Biomarker	[205]
SUPT20H	OTTMC0LH	Strong	Altered Expression	[623]
SUPT3H	OT7B6FRO	Strong	Altered Expression	[623]
TALDO1	OTDKV2S2	Strong	Genetic Variation	[624]
TBP	OT6C0S52	Strong	Altered Expression	[598]
TCF21	OT393IMA	Strong	Posttranslational Modification	[625]
TFAM	OTXXV5V7	Strong	Biomarker	[626]
TFDP2	OTKQFX5H	Strong	Genetic Variation	[627]
TFE3	OTM99ZWH	Strong	Biomarker	[628]
THEM4	OTSIZU8Y	Strong	Biomarker	[629]
TIMP3	OTDGQAD1	Strong	Genetic Variation	[630]
TMC6	OTKH50J4	Strong	Biomarker	[631]
TMEM45A	OT54KJG6	Strong	Altered Expression	[632]
TMPRSS11E	OTO5U2TK	Strong	Altered Expression	[633]
TMPRSS13	OTMAOAP3	Strong	Posttranslational Modification	[247]
TNFAIP2	OTRZH80H	Strong	Genetic Variation	[634]
TNFAIP8	OT1G9297	Strong	Biomarker	[635]
TP53I3	OTSCM68G	Strong	Genetic Variation	[550]
TP53INP2	OT0GTBXO	Strong	Biomarker	[509]
TP73	OT0LUO47	Strong	Genetic Variation	[442]
TRAF4	OTJLRVMC	Strong	Altered Expression	[636]
TRIM33	OT0KS4J7	Strong	Biomarker	[637]
TRIP13	OTFM3TI9	Strong	Biomarker	[638]
TSPAN1	OTZQPIYK	Strong	Biomarker	[639]
TSPAN31	OT8WQ83R	Strong	Altered Expression	[116]
HOXD10	OT0NOWU2	Definitive	Altered Expression	[640]
TP63	OT0WOOKQ	Definitive	Biomarker	[641]
------------------------------------------------------------------------------------


⏷ Show the Full List of 480 DOT(s)

References

1	Clinical pipeline report, company report or official report of CEL-SCI
2	ClinicalTrials.gov (NCT05271604) A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in PD-1/L1 Failure Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. U.S.National Institutes of Health.
3	ClinicalTrials.gov (NCT04096638) Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
4	Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma.PLoS One. 2014 Oct 2;9(9):e108908. doi: 10.1371/journal.pone.0108908. eCollection 2014.
5	The Integration of a Three-Dimensional Spheroid Cell Culture Operation in a Circulating Tumor Cell (CTC) Isolation and Purification Process: A Preliminary Study of the Clinical Significance and Prognostic Role of the CTCs Isolated from the Blood Samples of Head and Neck Cancer Patients.Cancers (Basel). 2019 Jun 6;11(6):783. doi: 10.3390/cancers11060783.
6	Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma.Lab Invest. 2016 May;96(5):508-16. doi: 10.1038/labinvest.2015.163. Epub 2016 Feb 29.
7	A novel splice variant of LOXL2 promotes progression of human papillomavirus-negative head and neck squamous cell carcinoma.Cancer. 2020 Feb 15;126(4):737-748. doi: 10.1002/cncr.32610. Epub 2019 Nov 13.
8	Heavy alcohol drinking downregulates ALDH2 gene expression but heavy smoking up-regulates SOD2 gene expression in head and neck squamous cell carcinoma.World J Surg Oncol. 2017 Aug 25;15(1):163. doi: 10.1186/s12957-017-1225-1.
9	Analysis of autophagy gene polymorphisms in Spanish patients with head and neck squamous cell carcinoma.Sci Rep. 2017 Jul 31;7(1):6887. doi: 10.1038/s41598-017-07270-0.
10	Genetic variants of a BH3-only pro-apoptotic gene, PUMA, and risk of HPV16-associated squamous cell carcinoma of the head and neck.Mol Carcinog. 2012 Oct;51 Suppl 1(Suppl 1):E54-64. doi: 10.1002/mc.21838. Epub 2011 Nov 15.
11	CD147 mediates transforming growth factor-1-induced epithelial-mesenchymal transition and cell invasion in squamous cell carcinoma of the tongue.Exp Ther Med. 2019 Apr;17(4):2855-2860. doi: 10.3892/etm.2019.7230. Epub 2019 Jan 31.
12	Drug repositioning in head and neck squamous cell carcinoma: An integrated pathway analysis based on connectivity map and differential gene expression.Pathol Res Pract. 2019 Jun;215(6):152378. doi: 10.1016/j.prp.2019.03.007. Epub 2019 Mar 5.
13	Head-and-neck squamous cell carcinoma risk in smokers: no association detected between phenotype and AHR, CYP1A1, CYP1A2, or CYP1B1 genotype.Hum Genomics. 2016 Nov 28;10(1):39. doi: 10.1186/s40246-016-0094-y.
14	DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.Int J Oncol. 2019 Mar;54(3):1021-1032. doi: 10.3892/ijo.2018.4667. Epub 2018 Dec 14.
15	Corrigendum: A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.Sci Rep. 2017 Jun 26;7:46864. doi: 10.1038/srep46864.
16	eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy.PLoS One. 2019 Nov 22;14(11):e0225537. doi: 10.1371/journal.pone.0225537. eCollection 2019.
17	Inhibition of cisplatin-resistant head and neck squamous cell carcinoma by combination of Afatinib with PD0325901, a MEK inhibitor.Am J Cancer Res. 2019 Jun 1;9(6):1282-1292. eCollection 2019.
18	Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck.J Clin Med. 2019 Dec 3;8(12):2131. doi: 10.3390/jcm8122131.
19	Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinoma.PLoS One. 2013 Nov 20;8(11):e80828. doi: 10.1371/journal.pone.0080828. eCollection 2013.
20	Osteoactivin regulates head and neck squamous cell carcinoma invasion by modulating matrix metalloproteases.J Cell Physiol. 2018 Jan;233(1):409-421. doi: 10.1002/jcp.25900. Epub 2017 Apr 25.
21	GTSP1 expression in non-smoker and non-drinker patients with squamous cell carcinoma of the head and neck.PLoS One. 2017 Aug 17;12(8):e0182600. doi: 10.1371/journal.pone.0182600. eCollection 2017.
22	Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.Oncotarget. 2016 Nov 15;7(46):76087-76100. doi: 10.18632/oncotarget.12590.
23	Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses.BMC Cancer. 2019 Jan 14;19(1):64. doi: 10.1186/s12885-018-5243-3.
24	Reactivation of super-enhancers by KLF4 in human Head and Neck Squamous Cell Carcinoma.Oncogene. 2020 Jan;39(2):262-277. doi: 10.1038/s41388-019-0990-4. Epub 2019 Sep 2.
25	Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1.Oncotarget. 2019 Jan 11;10(4):494-510. doi: 10.18632/oncotarget.26563. eCollection 2019 Jan 11.
26	Early Growth Response 1-Dependent Downregulation of Matrix Metalloproteinase 9 and Mouse Double Minute 2 Attenuates Head and Neck Squamous Cell Carcinoma Metastasis.Cell Physiol Biochem. 2018;50(5):1869-1881. doi: 10.1159/000494867. Epub 2018 Nov 5.
27	Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck.Carcinogenesis. 2013 Jul;34(7):1551-7. doi: 10.1093/carcin/bgt096. Epub 2013 Mar 18.
28	Discretionary Transduction of MMP-Sensitized Tousled in Head and Neck Cancer.Mol Ther Oncolytics. 2019 Mar 20;14:57-65. doi: 10.1016/j.omto.2019.02.003. eCollection 2019 Sep 27.
29	Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma.Biomolecules. 2019 Sep 30;9(10):550. doi: 10.3390/biom9100550.
30	PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.Clin Cancer Res. 2019 Jun 1;25(11):3329-3340. doi: 10.1158/1078-0432.CCR-18-3276. Epub 2019 Feb 15.
31	Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma.BMC Cancer. 2018 Nov 12;18(1):1107. doi: 10.1186/s12885-018-4965-6.
32	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer.Clin Cancer Res. 2016 Sep 15;22(18):4643-50. doi: 10.1158/1078-0432.CCR-15-2785. Epub 2016 Apr 1.
33	Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma.Br J Cancer. 2016 Sep 27;115(7):825-30. doi: 10.1038/bjc.2016.266. Epub 2016 Sep 1.
34	RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.Clin Cancer Res. 2013 Jul 1;19(13):3416-28. doi: 10.1158/1078-0432.CCR-13-0073. Epub 2013 May 29.
35	Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer.J Exp Clin Cancer Res. 2018 Mar 5;37(1):44. doi: 10.1186/s13046-018-0713-7.
36	Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
37	Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact.PLoS One. 2010 Aug 16;5(8):e12178. doi: 10.1371/journal.pone.0012178.
38	Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.Mol Pharm. 2019 Feb 4;16(2):701-708. doi: 10.1021/acs.molpharmaceut.8b00950. Epub 2018 Dec 31.
39	The role of acetyl-coA carboxylase2 in head and neck squamous cell carcinoma.PeerJ. 2019 Jun 11;7:e7037. doi: 10.7717/peerj.7037. eCollection 2019.
40	Detailed analysis of adenosine A2a receptor (ADORA2A) and CD73 (5'-nucleotidase, ecto, NT5E) methylation and gene expression in head and neck squamous cell carcinoma patients.Oncoimmunology. 2018 Apr 18;7(8):e1452579. doi: 10.1080/2162402X.2018.1452579. eCollection 2018.
41	Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cells.Int J Cancer. 2020 Jul 1;147(1):202-217. doi: 10.1002/ijc.32835. Epub 2020 Jan 9.
42	AGR2 promotes the proliferation, migration and regulates epithelial-mesenchymal transition in salivary adenoid cystic carcinoma.Am J Transl Res. 2017 Feb 15;9(2):507-519. eCollection 2017.
43	Epidermal growth factor-induced ANGPTL4 enhances anoikis resistance and tumour metastasis in head and neck squamous cell carcinoma.Oncogene. 2017 Apr 20;36(16):2228-2242. doi: 10.1038/onc.2016.371. Epub 2016 Oct 31.
44	Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.J Exp Clin Cancer Res. 2019 Feb 18;38(1):84. doi: 10.1186/s13046-019-1080-8.
45	p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells.Mol Oncol. 2018 Jun;12(6):788-798. doi: 10.1002/1878-0261.12172. Epub 2018 Apr 17.
46	LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.Mol Cancer Ther. 2019 Jun;18(6):1025-1035. doi: 10.1158/1535-7163.MCT-18-1157. Epub 2019 Apr 23.
47	Loss of heterozygosity in FANCG, FANCF and BRIP1 from head and neck squamous cell carcinoma of the oral cavity.Int J Oncol. 2017 Jun;50(6):2207-2220. doi: 10.3892/ijo.2017.3974. Epub 2017 Apr 24.
48	pDC depletion induced by CD317 blockade drives the antitumor immune response in head and neck squamous cell carcinoma.Oral Oncol. 2019 Sep;96:131-139. doi: 10.1016/j.oraloncology.2019.07.019. Epub 2019 Jul 26.
49	Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.Oncotarget. 2017 Mar 21;8(12):18726-18734. doi: 10.18632/oncotarget.9640.
50	Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.J Exp Clin Cancer Res. 2018 Oct 30;37(1):264. doi: 10.1186/s13046-018-0942-9.
51	CD200 Induces Epithelial-to-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma via -Catenin-Mediated Nuclear Translocation.Cancers (Basel). 2019 Oct 17;11(10):1583. doi: 10.3390/cancers11101583.
52	Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma.J Cell Mol Med. 2017 Sep;21(9):2199-2210. doi: 10.1111/jcmm.13143. Epub 2017 Apr 11.
53	Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.Int J Cancer. 2017 Mar 1;140(5):1173-1185. doi: 10.1002/ijc.30493. Epub 2016 Dec 2.
54	CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma.Oral Oncol. 2018 Mar;78:145-150. doi: 10.1016/j.oraloncology.2018.01.024. Epub 2018 Feb 20.
55	Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine's down regulation of cell cycle processes in OSCC cells. Oncotarget. 2017 Dec 20;9(5):5797-5810.
56	Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.Cancer Lett. 2020 Jan 28;469:510-523. doi: 10.1016/j.canlet.2019.11.027. Epub 2019 Nov 22.
57	Screening and clinical significance of tumor markers in head and neck squamous cell carcinoma through bioinformatics analysis.Mol Med Rep. 2019 Jan;19(1):143-154. doi: 10.3892/mmr.2018.9639. Epub 2018 Nov 9.
58	Can gene editing and silencing technologies play a role in the treatment of head and neck cancer?.Oral Oncol. 2017 May;68:9-19. doi: 10.1016/j.oraloncology.2017.02.016. Epub 2017 Mar 10.
59	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.JAMA Oncol. 2017 Feb 1;3(2):244-255. doi: 10.1001/jamaoncol.2016.1790.
60	Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.BMC Cancer. 2018 Jan 6;18(1):46. doi: 10.1186/s12885-017-3907-z.
61	Evaluation of the cancer stem cell marker DCLK1 in patients with lymph node metastases of head and neck cancer.Pathol Res Pract. 2019 Dec;215(12):152698. doi: 10.1016/j.prp.2019.152698. Epub 2019 Oct 23.
62	Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma.Br J Cancer. 2018 Feb 20;118(4):509-521. doi: 10.1038/bjc.2017.442. Epub 2018 Jan 18.
63	Apoptosis-sensitizing activity of birinapant in head and neck squamous cell carcinoma cell lines.Oncol Lett. 2018 Mar;15(3):4010-4016. doi: 10.3892/ol.2018.7783. Epub 2018 Jan 12.
64	The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.Mol Cancer Ther. 2018 Feb;17(2):368-380. doi: 10.1158/1535-7163.MCT-17-0083. Epub 2017 Aug 24.
65	ECE-1 overexpression in head and neck cancer is associated with poor tumor differentiation and patient outcome.Oral Dis. 2019 Jan;25(1):44-53. doi: 10.1111/odi.12935. Epub 2018 Oct 21.
66	Ectonucleotidase CD39 expression in regional metastases in head and neck cancer.Acta Otolaryngol. 2018 Apr;138(4):428-432. doi: 10.1080/00016489.2017.1405278. Epub 2017 Nov 26.
67	Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.Int J Radiat Biol. 2019 Dec;95(12):1597-1612. doi: 10.1080/09553002.2019.1664787. Epub 2019 Sep 17.
68	NET-producing CD16(high) CD62L(dim) neutrophils migrate to tumor sites and predict improved survival in patients with HNSCC.Int J Cancer. 2017 Jun 1;140(11):2557-2567. doi: 10.1002/ijc.30671. Epub 2017 Mar 11.
69	Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.Head Neck. 2018 Nov;40(11):2424-2431. doi: 10.1002/hed.25353. Epub 2018 Oct 10.
70	Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance.Cancer Lett. 2017 Feb 1;386:87-99. doi: 10.1016/j.canlet.2016.11.014. Epub 2016 Nov 17.
71	FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma.Oncogene. 2019 Mar;38(13):2394-2404. doi: 10.1038/s41388-018-0591-7. Epub 2018 Dec 5.
72	VEGF-C/Flt-4 axis in tumor cells contributes to the progression of oral squamous cell carcinoma via upregulating VEGF-C itself and contactin-1 in an autocrine manner.Am J Cancer Res. 2018 Oct 1;8(10):2046-2063. eCollection 2018.
73	Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.Acta Biomater. 2017 Jul 15;57:251-261. doi: 10.1016/j.actbio.2017.04.023. Epub 2017 Apr 22.
74	Ferritin: A potential serum marker for lymph node metastasis in head and neck squamous cell carcinoma.Oncol Lett. 2019 Jan;17(1):314-322. doi: 10.3892/ol.2018.9642. Epub 2018 Oct 30.
75	Identification of guanine nucleotide-binding protein -7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling.Int J Oncol. 2013 Apr;42(4):1427-36. doi: 10.3892/ijo.2013.1808. Epub 2013 Feb 6.
76	Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers.Int J Mol Sci. 2019 Oct 11;20(20):5027. doi: 10.3390/ijms20205027.
77	G-protein-coupled receptor kinase 2 safeguards epithelial phenotype in head and neck squamous cell carcinomas.Int J Cancer. 2020 Jul 1;147(1):218-229. doi: 10.1002/ijc.32838. Epub 2020 Jan 7.
78	Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma.Br J Cancer. 2017 Dec 5;117(12):1810-1818. doi: 10.1038/bjc.2017.373. Epub 2017 Nov 2.
79	Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma.Br J Cancer. 2019 Feb;120(3):317-330. doi: 10.1038/s41416-018-0352-y. Epub 2018 Dec 17.
80	Association between a functional polymorphism (-1195T>C) in the IGFBP5 promoter and head and neck cancer risk.Head Neck. 2011 May;33(5):650-60. doi: 10.1002/hed.21514. Epub 2010 Oct 14.
81	Targeting of interleukin-13 receptor 2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF- and PTEN signaling.J Transl Med. 2013 Feb 19;11:45. doi: 10.1186/1479-5876-11-45.
82	Bifidobacterium breve as a delivery vector of IL-24 gene therapy for head and neck squamous cell carcinoma in vivo.Gene Ther. 2017 Nov;24(11):699-705. doi: 10.1038/gt.2017.74. Epub 2017 Aug 14.
83	Integrin 11 is overexpressed by tumour stroma of head and neck squamous cell carcinoma and correlates positively with alpha smooth muscle actin expression.J Oral Pathol Med. 2017 Apr;46(4):267-275. doi: 10.1111/jop.12493. Epub 2016 Oct 4.
84	Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma.J Exp Clin Cancer Res. 2019 Jun 25;38(1):278. doi: 10.1186/s13046-019-1254-4.
85	KDM5B overexpression predicts a poor prognosis in patients with squamous cell carcinoma of the head and neck.J Cancer. 2018 Jan 1;9(1):198-204. doi: 10.7150/jca.22145. eCollection 2018.
86	KIR2DS4, KIR2DL2, and KIR2DS4del are linked with basaloid tumors, lymph node metastasis, advanced stage and metastatic risk in head and neck squamous cell carcinoma.Exp Mol Pathol. 2020 Feb;112:104345. doi: 10.1016/j.yexmp.2019.104345. Epub 2019 Nov 18.
87	Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma.Front Immunol. 2017 Apr 10;8:387. doi: 10.3389/fimmu.2017.00387. eCollection 2017.
88	LAMB3 is associated with disease progression and cisplatin cytotoxic sensitivity in head and neck squamous cell carcinoma.Eur J Surg Oncol. 2019 Mar;45(3):359-365. doi: 10.1016/j.ejso.2018.10.543. Epub 2018 Nov 2.
89	Overexpression of LAPTM4B-35 is a negative prognostic factor in head and neck squamous cell carcinoma.Sci Rep. 2019 Dec 11;9(1):18866. doi: 10.1038/s41598-019-55319-z.
90	LASP1 promotes proliferation, metastasis, invasion in head and neck squamous cell carcinoma and through direct interaction with HSPA1A.J Cell Mol Med. 2020 Jan;24(2):1626-1639. doi: 10.1111/jcmm.14854. Epub 2019 Dec 2.
91	Lymphotoxin- promotes tumor angiogenesis in HNSCC by modulating glycolysis in a PFKFB3-dependent manner.Int J Cancer. 2019 Sep 1;145(5):1358-1370. doi: 10.1002/ijc.32221. Epub 2019 Mar 6.
92	Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1.Cancer Med. 2018 Jul;7(7):3178-3187. doi: 10.1002/cam4.1529. Epub 2018 May 15.
93	PRRX1 Regulates Cellular Phenotype Plasticity and Dormancy of Head and Neck Squamous Cell Carcinoma Through miR-642b-3p.Neoplasia. 2019 Feb;21(2):216-229. doi: 10.1016/j.neo.2018.12.001. Epub 2019 Jan 7.
94	MAPKAPK2 plays a crucial role in the progression of head and neck squamous cell carcinoma by regulating transcript stability.J Exp Clin Cancer Res. 2019 Apr 25;38(1):175. doi: 10.1186/s13046-019-1167-2.
95	High expression of MLANA in the plasma of patients with head and neck squamous cell carcinoma as a predictor of tumor progression.Head Neck. 2019 May;41(5):1199-1205. doi: 10.1002/hed.25510. Epub 2019 Feb 25.
96	CD44(+) tumor cells promote early angiogenesis in head and neck squamous cell carcinoma.Cancer Lett. 2019 Dec 28;467:85-95. doi: 10.1016/j.canlet.2019.10.010. Epub 2019 Oct 5.
97	Non-muscle myosin II as a predictive factor in head and neck squamous cell carcinoma.Med Oral Patol Oral Cir Bucal. 2019 May 1;24(3):e346-e353. doi: 10.4317/medoral.22898.
98	The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.Cell Prolif. 2019 Mar;52(2):e12536. doi: 10.1111/cpr.12536. Epub 2018 Oct 19.
99	Integrative Bioinformatics Analysis Identifies NEK2 as a Potential Biomarker in Head and Neck Squamous Cell Carcinoma.J Comput Biol. 2020 Jan;27(1):100-108. doi: 10.1089/cmb.2019.0208. Epub 2019 Aug 28.
100	Associations between expression levels of nucleotide excision repair proteins in lymphoblastoid cells and risk of squamous cell carcinoma of the head and neck.Mol Carcinog. 2018 Jun;57(6):784-793. doi: 10.1002/mc.22801. Epub 2018 Mar 25.
101	NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma.Sci Rep. 2017 Dec 6;7(1):17064. doi: 10.1038/s41598-017-17298-x.
102	Nerve Growth Factor (NGF)-Receptor Survival Axis in Head and Neck Squamous Cell Carcinoma.Int J Mol Sci. 2018 Jun 14;19(6):1771. doi: 10.3390/ijms19061771.
103	Altered DNA methylation is associated with aberrant stemness gene expression in earlystage HNSCC.Int J Oncol. 2019 Oct;55(4):915-924. doi: 10.3892/ijo.2019.4857. Epub 2019 Aug 14.
104	Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck.Head Neck. 2019 Jun;41(6):1979-1983. doi: 10.1002/hed.25627. Epub 2019 Jan 11.
105	Integrative genomic analysis identifies ancestry-related expression quantitative trait loci on DNA polymerase and supports the association of genetic ancestry with survival disparities in head and neck squamous cell carcinoma.Cancer. 2017 Mar 1;123(5):849-860. doi: 10.1002/cncr.30457. Epub 2016 Dec 1.
106	Periostin secreted by cancer-associated fibroblasts promotes cancer stemness in head and neck cancer by activating protein tyrosine kinase 7.Cell Death Dis. 2018 Oct 22;9(11):1082. doi: 10.1038/s41419-018-1116-6.
107	Bioinformatics-based discovery of PYGM and TNNC2 as potential biomarkers of head and neck squamous cell carcinoma.Biosci Rep. 2019 Jul 29;39(7):BSR20191612. doi: 10.1042/BSR20191612. Print 2019 Jul 31.
108	Rh type C-glycoprotein functions as a novel tumor suppressor gene by inhibiting tumorigenicity and metastasis in head and neck squamous cell carcinoma.Aging (Albany NY). 2019 Jun 6;11(11):3601-3623. doi: 10.18632/aging.102000.
109	Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.Mol Oncol. 2019 Oct;13(10):2160-2177. doi: 10.1002/1878-0261.12558. Epub 2019 Aug 28.
110	Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.Carcinogenesis. 2016 May;37(5):522-9. doi: 10.1093/carcin/bgw032. Epub 2016 Mar 18.
111	Monocarboxylate Transporter 4 (MCT4) Knockout Mice Have Attenuated 4NQO Induced Carcinogenesis; A Role for MCT4 in Driving Oral Squamous Cell Cancer.Front Oncol. 2018 Aug 28;8:324. doi: 10.3389/fonc.2018.00324. eCollection 2018.
112	Glucose transporter 4 promotes head and neck squamous cell carcinoma metastasis through the TRIM24-DDX58 axis.J Hematol Oncol. 2017 Jan 7;10(1):11. doi: 10.1186/s13045-016-0372-0.
113	ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.Br J Cancer. 2020 Jan;122(1):82-93. doi: 10.1038/s41416-019-0637-9. Epub 2019 Dec 10.
114	Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients.Oral Oncol. 2019 Feb;89:72-78. doi: 10.1016/j.oraloncology.2018.12.010. Epub 2018 Dec 21.
115	Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.Cancer Sci. 2019 Nov;110(11):3453-3463. doi: 10.1111/cas.14182. Epub 2019 Sep 13.
116	Elevated Na(+)/H(+) exchanger-1 expression enhances the metastatic collective migration of head and neck squamous cell carcinoma cells.Biochem Biophys Res Commun. 2017 Apr 22;486(1):101-107. doi: 10.1016/j.bbrc.2017.03.007. Epub 2017 Mar 6.
117	Transporter gene expression in human head and neck squamous cell carcinoma and associated epigenetic regulatory mechanisms. Am J Pathol. 2013 Jan;182(1):234-43. doi: 10.1016/j.ajpath.2012.09.008. Epub 2012 Nov 6.
118	Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma.Auris Nasus Larynx. 2018 Aug;45(4):854-865. doi: 10.1016/j.anl.2017.11.019. Epub 2017 Dec 9.
119	STOML2 as a novel prognostic biomarker modulates cell proliferation, motility and chemo-sensitivity via IL6-Stat3 pathway in head and neck squamous cell carcinoma.Am J Transl Res. 2019 Feb 15;11(2):683-695. eCollection 2019.
120	Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.Cell Death Dis. 2018 Jan 5;9(1):5. doi: 10.1038/s41419-017-0029-0.
121	Circulating extracellular vesicle-associated TGF3 modulates response to cytotoxic therapy in head and neck squamous cell carcinoma.Carcinogenesis. 2019 Dec 31;40(12):1452-1461. doi: 10.1093/carcin/bgz148.
122	Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.Cancer Immunol Res. 2019 Oct;7(10):1700-1713. doi: 10.1158/2326-6066.CIR-18-0725. Epub 2019 Aug 6.
123	Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.Clin Cancer Res. 2018 Jan 1;24(1):62-72. doi: 10.1158/1078-0432.CCR-17-0357. Epub 2017 Oct 23.
124	Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.Sci Rep. 2017 Aug 22;7(1):9031. doi: 10.1038/s41598-017-09539-w.
125	Association of OX40 gene polymorphisms (rs17568G/A and rs229811A/C) with head and neck squamous cell carcinoma.Mol Biol Rep. 2019 Jun;46(3):2609-2616. doi: 10.1007/s11033-019-04602-3. Epub 2019 Mar 28.
126	TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects.Oncogene. 2017 Feb 9;36(6):820-828. doi: 10.1038/onc.2016.250. Epub 2016 Jul 18.
127	Np63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis.Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13254-13259. doi: 10.1073/pnas.1711777114. Epub 2017 Nov 21.
128	A single nucleotide polymorphism in the alcohol dehydrogenase 7 gene (alanine to glycine substitution at amino acid 92) is associated with the risk of squamous cell carcinoma of the head and neck.Cancer. 2010 Jun 15;116(12):2984-92. doi: 10.1002/cncr.25058.
129	Recent advances in TMEM16A: Structure, function, and disease.J Cell Physiol. 2019 Jun;234(6):7856-7873. doi: 10.1002/jcp.27865. Epub 2018 Dec 4.
130	A preliminary investigation of circulating extracellular vesicles and biomarker discovery associated with treatment response in head and neck squamous cell carcinoma.BMC Cancer. 2019 Apr 23;19(1):373. doi: 10.1186/s12885-019-5565-9.
131	Modulation of L-Arginine-Arginase Metabolic Pathway Enzymes: Immunocytochemistry and mRNA Expression in Peripheral Blood and Tissue Levels in Head and Neck Squamous Cell Carcinomas in North East India.Asian Pac J Cancer Prev. 2015;16(16):7031-8. doi: 10.7314/apjcp.2015.16.16.7031.
132	ATP2A3 gene is involved in cancer susceptibility.Cancer Genet Cytogenet. 2009 Jan 15;188(2):88-94. doi: 10.1016/j.cancergencyto.2008.10.007.
133	Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.Clin Cancer Res. 2019 Jun 1;25(11):3430-3442. doi: 10.1158/1078-0432.CCR-18-0440. Epub 2019 Feb 12.
134	Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins.Cancer Lett. 2014 Nov 28;354(2):365-77. doi: 10.1016/j.canlet.2014.08.039. Epub 2014 Sep 2.
135	Association between ADH1B and ADH1C polymorphisms and the risk of head and neck squamous cell carcinoma.Tumour Biol. 2015 Jun;36(6):4387-96. doi: 10.1007/s13277-015-3078-y. Epub 2015 Jan 21.
136	MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.Mol Cancer Ther. 2018 Nov;17(11):2297-2308. doi: 10.1158/1535-7163.MCT-17-1239. Epub 2018 Aug 9.
137	Elemental Zn and its Binding Protein Zinc-2-Glycoprotein are Elevated in HPV-Positive Oropharyngeal Squamous Cell Carcinoma.Sci Rep. 2019 Nov 18;9(1):16965. doi: 10.1038/s41598-019-53268-1.
138	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
139	Mutation analysis of hBUB1 in aneuploid HNSCC and lung cancer cell lines.Cancer Lett. 1999 May 24;139(2):183-7. doi: 10.1016/s0304-3835(99)00035-x.
140	ERCC1 C8092A polymorphism predicts fair survival outcome in Japanese patients with pharyngo-laryngeal squamous cell carcinoma.Eur Arch Otorhinolaryngol. 2020 Feb;277(2):601-610. doi: 10.1007/s00405-019-05731-y. Epub 2019 Nov 20.
141	A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer.FASEB J. 2013 Apr;27(4):1404-12. doi: 10.1096/fj.12-223420. Epub 2012 Dec 27.
142	The non-coding landscape of head and neck squamous cell carcinoma.Oncotarget. 2016 Aug 9;7(32):51211-51222. doi: 10.18632/oncotarget.9979.
143	Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.Laryngoscope. 2001 Jun;111(6):982-8. doi: 10.1097/00005537-200106000-00010.
144	Aberrant Myosin 1b Expression Promotes Cell Migration and Lymph Node Metastasis of HNSCC.Mol Cancer Res. 2015 Apr;13(4):721-31. doi: 10.1158/1541-7786.MCR-14-0410. Epub 2014 Nov 24.
145	Hsa-let-7e-5p Inhibits the Proliferation and Metastasis of Head and Neck Squamous Cell Carcinoma Cells by Targeting Chemokine Receptor 7.J Cancer. 2019 Apr 25;10(8):1941-1948. doi: 10.7150/jca.29536. eCollection 2019.
146	Prognostic significance of CD68(+) and CD163(+) tumor associated macrophages in head and neck squamous cell carcinoma: A systematic review and meta-analysis.Oral Oncol. 2019 Jun;93:66-75. doi: 10.1016/j.oraloncology.2019.04.019. Epub 2019 Apr 28.
147	NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.BMC Cancer. 2015 Oct 30;15:825. doi: 10.1186/s12885-015-1806-8.
148	Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.Head Neck. 2020 Apr;42(4):774-786. doi: 10.1002/hed.26036. Epub 2019 Nov 24.
149	Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.Oncol Rep. 2009 Jan;21(1):165-71.
150	Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma.Oncoimmunology. 2018 Mar 13;7(4):e1397248. doi: 10.1080/2162402X.2017.1397248. eCollection 2018.
151	Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.Cancer Immunol Immunother. 2009 Nov;58(11):1853-64. doi: 10.1007/s00262-009-0697-4. Epub 2009 Mar 25.
152	Motility-related protein-1/CD9 expression in head and neck squamous cell carcinoma.Head Neck. 2003 Oct;25(10):848-57. doi: 10.1002/hed.10306.
153	Preferential allelic deletion of RBSP3, LIMD1 and CDC25A in head and neck squamous cell carcinoma: Implication in cancer screening and early detection.Cancer Biol Ther. 2018 Jul 3;19(7):631-635. doi: 10.1080/15384047.2018.1449615. Epub 2018 Apr 13.
154	CDH11 inhibits proliferation and invasion in head and neck cancer.J Oral Pathol Med. 2017 Feb;46(2):89-97. doi: 10.1111/jop.12471. Epub 2016 Jul 10.
155	CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An In Vitro Study.Anticancer Res. 2019 Feb;39(2):713-720. doi: 10.21873/anticanres.13167.
156	Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis.Mol Cancer. 2012 Sep 28;11:74. doi: 10.1186/1476-4598-11-74.
157	Promoter methylation of cyclin A1 is associated with human papillomavirus 16 induced head and neck squamous cell carcinoma independently of p53 mutation.Mol Carcinog. 2011 Sep;50(9):680-8. doi: 10.1002/mc.20798. Epub 2011 May 11.
158	Identification and analysis of genes associated with head and neck squamous cell carcinoma by integrated bioinformatics methods.Mol Genet Genomic Med. 2019 Aug;7(8):e857. doi: 10.1002/mgg3.857. Epub 2019 Jul 15.
159	Functional and genomic analyses reveal therapeutic potential of targeting -catenin/CBP activity in head and neck cancer.Genome Med. 2018 Jul 20;10(1):54. doi: 10.1186/s13073-018-0569-7.
160	CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.Clin Cancer Res. 2010 Apr 15;16(8):2295-307. doi: 10.1158/1078-0432.CCR-09-3200. Epub 2010 Apr 6.
161	Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients.Int J Cancer. 2014 Dec 1;135(11):2727-34. doi: 10.1002/ijc.28906. Epub 2014 Apr 26.
162	Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer.PLoS One. 2009;4(3):e4961. doi: 10.1371/journal.pone.0004961. Epub 2009 Mar 23.
163	The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.Oral Oncol. 2019 Mar;90:67-73. doi: 10.1016/j.oraloncology.2019.01.018. Epub 2019 Feb 5.
164	Association of cytochrome P450 1B1 haplotypes with head and neck cancer risk.Environ Mol Mutagen. 2017 Jul;58(6):443-450. doi: 10.1002/em.22098. Epub 2017 May 28.
165	The effect of cellular retinoic acid binding protein-I expression on the CYP26-mediated catabolism of all-trans retinoic acid and cell proliferation in head and neck squamous cell carcinoma.Metabolism. 2004 Aug;53(8):1007-12. doi: 10.1016/j.metabol.2003.12.015.
166	Polymorphisms in alcohol and tobacco metabolism genes in head and neck cancer in the Basque Country.J Oral Pathol Med. 2015 Nov;44(10):769-75. doi: 10.1111/jop.12305. Epub 2015 Jan 31.
167	The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.Cell Oncol (Dordr). 2012 Feb;35(1):1-8. doi: 10.1007/s13402-011-0051-7. Epub 2011 Jun 8.
168	L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study.BMC Cancer. 2012 Oct 20;12:484. doi: 10.1186/1471-2407-12-484.
169	Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma.Neoplasia. 2008 Nov;10(11):1295-302. doi: 10.1593/neo.08586.
170	Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma.Cancer Biol Ther. 2014 May;15(5):612-22. doi: 10.4161/cbt.28181. Epub 2014 Feb 20.
171	Overexpression of p68 mRNA in head and neck squamous cell carcinoma cells.Anticancer Res. 2006 May-Jun;26(3A):1941-6.
172	Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma.Transl Oncol. 2018 Feb;11(1):168-174. doi: 10.1016/j.tranon.2017.12.001. Epub 2017 Dec 28.
173	Histogram analysis parameters identify multiple associations between DWI and DCE MRI in head and neck squamous cell carcinoma.Magn Reson Imaging. 2018 Jan;45:72-77. doi: 10.1016/j.mri.2017.09.015. Epub 2017 Sep 28.
174	Up-regulation of Histone Methyltransferase, DOT1L, by Matrix Hyaluronan Promotes MicroRNA-10 Expression Leading to Tumor Cell Invasion and Chemoresistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma.J Biol Chem. 2016 May 13;291(20):10571-85. doi: 10.1074/jbc.M115.700021. Epub 2016 Mar 21.
175	Correlation of tumor marker expression with nodal disease burden in metastatic head and neck cancer.Otolaryngol Head Neck Surg. 2013 Aug;149(2):261-8. doi: 10.1177/0194599813486876. Epub 2013 Apr 26.
176	Combined effects of E2F1 and E2F2 polymorphisms on risk and early onset of squamous cell carcinoma of the head and neck.Mol Carcinog. 2012 Oct;51 Suppl 1(Suppl 1):E132-41. doi: 10.1002/mc.21882. Epub 2012 Feb 17.
177	Expression levels of insulin-like growth factors 1 and 2 in head and neck squamous cell carcinoma.Growth Horm IGF Res. 2014 Aug;24(4):137-41. doi: 10.1016/j.ghir.2014.04.003. Epub 2014 Apr 22.
178	Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer.Hum Gene Ther Clin Dev. 2013 Sep;24(3):134-42. doi: 10.1089/humc.2013.144.
179	Serum biomarkers for detection of head and neck squamous cell carcinoma.Head Neck. 2016 Jan;38(1):9-14. doi: 10.1002/hed.23842. Epub 2015 Jun 26.
180	NGFI-A Binding Protein 2 Promotes EGF-Dependent HNSCC Cell Invasion.Cancers (Basel). 2019 Mar 6;11(3):315. doi: 10.3390/cancers11030315.
181	Hypoxic regulation of the PERK/ATF4/LAMP3-arm of the unfolded protein response in head and neck squamous cell carcinoma.Head Neck. 2015 Jun;37(6):896-905. doi: 10.1002/hed.23693. Epub 2014 Jun 27.
182	Caspase-mediated cleavage of RNA-binding protein HuR regulates c-Myc protein expression after hypoxic stress.J Biol Chem. 2011 Sep 16;286(37):32333-43. doi: 10.1074/jbc.M111.255927. Epub 2011 Jul 27.
183	Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils.Oral Oncol. 2017 Oct;73:77-82. doi: 10.1016/j.oraloncology.2017.08.010. Epub 2017 Aug 18.
184	Prognostic value of the expression of epithelial cell adhesion molecules in head and neck squamous cell carcinoma treated by definitive radiotherapy.J Radiat Res. 2019 Nov 22;60(6):803-811. doi: 10.1093/jrr/rrz053.
185	Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.Mol Cell Proteomics. 2011 Dec;10(12):M111.011635. doi: 10.1074/mcp.M111.011635. Epub 2011 Sep 28.
186	Epithelial-mesenchymal transition regulated by EphA2 contributes to vasculogenic mimicry formation of head and neck squamous cell carcinoma.Biomed Res Int. 2014;2014:803914. doi: 10.1155/2014/803914. Epub 2014 Apr 17.
187	Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma.Oncol Rep. 2012 Jul;28(1):172-8. doi: 10.3892/or.2012.1766. Epub 2012 Apr 20.
188	Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.Mol Cancer Ther. 2018 Sep;17(9):2049-2059. doi: 10.1158/1535-7163.MCT-17-1163. Epub 2018 Jul 3.
189	Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.Cancer Res. 2019 May 15;79(10):2722-2735. doi: 10.1158/0008-5472.CAN-18-3257. Epub 2019 Mar 20.
190	MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.Int J Cancer. 2019 Aug 1;145(3):748-762. doi: 10.1002/ijc.32170. Epub 2019 Feb 11.
191	Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.BMC Cancer. 2019 May 22;19(1):485. doi: 10.1186/s12885-019-5664-7.
192	Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma.Oncotarget. 2016 Jun 7;7(23):33887-900. doi: 10.18632/oncotarget.8432.
193	Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.PLoS One. 2016 Feb 29;11(2):e0148764. doi: 10.1371/journal.pone.0148764. eCollection 2016.
194	Effect of tumour-cell-derived or recombinant keratinocyte growth factor (KGF) on proliferation and radioresponse of human epithelial tumour cells (HNSCC) and normal keratinocytes in vitro.Radiat Environ Biophys. 2010 May;49(2):261-70. doi: 10.1007/s00411-010-0271-7. Epub 2010 Mar 7.
195	Mutation of chromatin regulators and focal hotspot alterations characterize human papillomavirus-positive oropharyngeal squamous cell carcinoma.Cancer. 2019 Jul 15;125(14):2423-2434. doi: 10.1002/cncr.32068. Epub 2019 Apr 1.
196	X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma.Oncotarget. 2016 Mar 22;7(12):14537-50. doi: 10.18632/oncotarget.7478.
197	The transcription factor FOXM1 regulates the balance between proliferation and aberrant differentiation in head and neck squamous cell carcinoma.J Pathol. 2020 Jan;250(1):107-119. doi: 10.1002/path.5342. Epub 2019 Dec 3.
198	Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: Potential utility as biomarkers for prognosis.Oncol Lett. 2018 Jun;15(6):9043-9050. doi: 10.3892/ol.2018.8525. Epub 2018 Apr 18.
199	Galanin is an epigenetically silenced tumor suppressor gene in gastric cancer cells.PLoS One. 2018 Feb 20;13(2):e0193275. doi: 10.1371/journal.pone.0193275. eCollection 2018.
200	Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.Clin Exp Metastasis. 2016 Feb;33(2):187-95. doi: 10.1007/s10585-015-9768-4. Epub 2015 Nov 16.
201	Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.Head Neck. 2019 Aug;41(8):2591-2601. doi: 10.1002/hed.25726. Epub 2019 Mar 4.
202	Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma.Head Neck. 2013 Feb;35(2):270-9. doi: 10.1002/hed.22963. Epub 2012 Mar 20.
203	Association of glutathione S-transferase omega gene polymorphisms with progression of head and neck cancer.Mol Biol Rep. 2012 Dec;39(12):10915-20. doi: 10.1007/s11033-012-1991-3. Epub 2012 Oct 20.
204	A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.Invest New Drugs. 2019 Aug;37(4):702-710. doi: 10.1007/s10637-018-0696-4. Epub 2018 Dec 19.
205	Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer.Mol Cancer. 2005 Apr 7;4(1):14. doi: 10.1186/1476-4598-4-14.
206	Weighted gene co-expression network analysis and prognostic analysis identifies hub genes and the molecular mechanism related to head and neck squamous cell carcinoma.Cancer Biol Ther. 2019;20(6):750-759. doi: 10.1080/15384047.2018.1564560. Epub 2019 Mar 22.
207	Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.Proteomics. 2015 Jan;15(2-3):383-93. doi: 10.1002/pmic.201400338.
208	Homeobox gene expression profile indicates HOXA5 as a candidate prognostic marker in oral squamous cell carcinoma.Int J Oncol. 2012 Apr;40(4):1180-8. doi: 10.3892/ijo.2011.1321. Epub 2011 Dec 29.
209	Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma.J Cell Mol Med. 2014 Jan;18(1):181-6. doi: 10.1111/jcmm.12179. Epub 2013 Nov 28.
210	p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells.J Clin Invest. 2010 Apr;120(4):1165-77. doi: 10.1172/JCI40582. Epub 2010 Mar 15.
211	Interleukin-28B acts synergistically with cisplatin to suppress the growth of head and neck squamous cell carcinoma.J Immunother. 2011 Mar;34(2):139-48. doi: 10.1097/CJI.0b013e318204ed70.
212	Np63 promotes IGF1 signalling through IRS1 in squamous cell carcinoma.Aging (Albany NY). 2018 Dec 28;10(12):4224-4240. doi: 10.18632/aging.101725.
213	Serum Levels of IGF-1 and IGFBP-3 in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas.Anticancer Res. 2017 Jun;37(6):3281-3286. doi: 10.21873/anticanres.11693.
214	Methylation status of insulin-like growth factor-binding protein 7 concurs with the malignance of oral tongue cancer.J Exp Clin Cancer Res. 2015 Feb 24;34(1):20. doi: 10.1186/s13046-015-0138-5.
215	Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.J Immunother Cancer. 2019 Mar 19;7(1):79. doi: 10.1186/s40425-019-0550-z.
216	Interleukin-4 receptor -based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma.Oncol Rep. 2013 Jun;29(6):2147-53. doi: 10.3892/or.2013.2387. Epub 2013 Apr 4.
217	Identification of molecular targets in head and neck squamous cell carcinomas based on genome-wide gene expression profiling.Oncol Rep. 2007 Dec;18(6):1489-97.
218	Frequent aberrant expression of the human ether go-go (hEAG1) potassium channel in head and neck cancer: pathobiological mechanisms and clinical implications.J Mol Med (Berl). 2012 Oct;90(10):1173-84. doi: 10.1007/s00109-012-0893-0. Epub 2012 Mar 31.
219	Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.Clin Cancer Res. 2013 Apr 15;19(8):1994-2003. doi: 10.1158/1078-0432.CCR-12-2539. Epub 2013 Feb 26.
220	KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene. 2011 Jul 14;30(28):3163-73. doi: 10.1038/onc.2011.39. Epub 2011 Mar 7.
221	Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas.Eur J Cancer. 2007 Jan;43(2):415-32. doi: 10.1016/j.ejca.2006.09.001. Epub 2006 Oct 31.
222	Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.Int J Biol Sci. 2014 Jun 21;10(7):702-14. doi: 10.7150/ijbs.9326. eCollection 2014.
223	Decreasing cytokeratin 17 expression in head and neck cancer predicts nodal metastasis and poor prognosis: The first evidence.Clin Otolaryngol. 2018 Aug;43(4):1010-1018. doi: 10.1111/coa.13092. Epub 2018 Apr 16.
224	Diagnostic potential of 1-step nucleic acid amplification assay in patients with head and neck squamous cell carcinoma based on CK19 expression in a primary lesion.Head Neck. 2016 Apr;38 Suppl 1:E239-45. doi: 10.1002/hed.23979. Epub 2015 Jun 25.
225	Determination of Pyruvate Metabolic Fates Modulates Head and Neck Tumorigenesis.Neoplasia. 2019 Jul;21(7):641-652. doi: 10.1016/j.neo.2019.04.007. Epub 2019 May 14.
226	Detection of Distinct Changes in Gene-expression Profiles in Specimens of Tumors and Transition Zones of Tenascin-positive/-negative Head and Neck Squamous Cell Carcinoma.Anticancer Res. 2018 Mar;38(3):1279-1290. doi: 10.21873/anticanres.12350.
227	Elevated exosomal lysyl oxidase like 2 is a potential biomarker for head and neck squamous cell carcinoma.Laryngoscope. 2020 May;130(5):E327-E334. doi: 10.1002/lary.28142. Epub 2019 Jun 20.
228	Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells.Int J Oncol. 2013 May;42(5):1560-8. doi: 10.3892/ijo.2013.1849. Epub 2013 Mar 5.
229	PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation. Oncotarget. 2017 Sep 26;9(2):1885-1897. doi: 10.18632/oncotarget.21277. eCollection 2018 Jan 5.
230	Lymphotoxin- Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.Clin Cancer Res. 2017 Aug 1;23(15):4388-4401. doi: 10.1158/1078-0432.CCR-16-1955. Epub 2017 Feb 14.
231	Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients.Clin Cancer Res. 2004 Dec 1;10(23):7827-33. doi: 10.1158/1078-0432.CCR-04-1090.
232	Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcin... Int J Cancer. 2003 Mar 1;103(6):768-74.
233	Lymphatic vessel density in vocal cord carcinomas assessed with LYVE-1 receptor expression.Radiother Oncol. 2005 Nov;77(2):172-5. doi: 10.1016/j.radonc.2005.09.013. Epub 2005 Oct 17.
234	A Comprehensive Expression Analysis of Cancer Testis Antigens in Head and Neck Squamous Cell Carcinoma Revels MAGEA3/6 as a Marker for Recurrence.Mol Cancer Ther. 2015 Mar;14(3):828-34. doi: 10.1158/1535-7163.MCT-14-0796. Epub 2015 Jan 6.
235	MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.Sci Rep. 2019 Dec 11;9(1):18793. doi: 10.1038/s41598-019-55208-5.
236	Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.Oncoimmunology. 2018 Sep 21;8(1):e1515057. doi: 10.1080/2162402X.2018.1515057. eCollection 2019.
237	Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.Cancer Res. 1993 Dec 1;53(23):5654-62.
238	Head and neck cancer cells and xenografts are very sensitive to palytoxin: decrease of c-jun n-terminale kinase-3 expression enhances palytoxin toxicity.Mol Cancer. 2013 Feb 14;12:12. doi: 10.1186/1476-4598-12-12.
239	Subpath analysis of each subtype of head and neck cancer based on the regulatory relationship between miRNAs and biological pathways.Oncol Rep. 2015 Oct;34(4):1745-54. doi: 10.3892/or.2015.4150. Epub 2015 Jul 24.
240	MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells.Oncol Rep. 2019 Apr;41(4):2540-2548. doi: 10.3892/or.2019.6988. Epub 2019 Jan 30.
241	A systematic review and meta-analysis approach on diagnostic value of MLH1 promoter methylation for head and neck squamous cell carcinoma.Medicine (Baltimore). 2019 Oct;98(43):e17651. doi: 10.1097/MD.0000000000017651.
242	p120-Catenin Downregulation and PIK3CA Mutations Cooperate to Induce Invasion through MMP1 in HNSCC.Mol Cancer Res. 2017 Oct;15(10):1398-1409. doi: 10.1158/1541-7786.MCR-17-0108. Epub 2017 Jun 21.
243	MMP-10/stromelysin-2 promotes invasion of head and neck cancer.PLoS One. 2011;6(10):e25438. doi: 10.1371/journal.pone.0025438. Epub 2011 Oct 5.
244	MT4-MMP promotes invadopodia formation and cell motility in FaDu head and neck cancer cells.Biochem Biophys Res Commun. 2020 Feb 19;522(4):1009-1014. doi: 10.1016/j.bbrc.2019.12.009. Epub 2019 Dec 5.
245	Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions.BMC Cancer. 2010 Jul 14;10:369. doi: 10.1186/1471-2407-10-369.
246	Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma.Int J Cancer. 2013 Jun 15;132(12):2755-66. doi: 10.1002/ijc.27966. Epub 2012 Dec 17.
247	Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin.Int J Biochem Cell Biol. 2013 Mar;45(3):513-20. doi: 10.1016/j.biocel.2012.12.004. Epub 2012 Dec 12.
248	miR-30e-5p represses angiogenesis and metastasis by directly targeting AEG-1 in squamous cell carcinoma of the head and neck.Cancer Sci. 2020 Feb;111(2):356-368. doi: 10.1111/cas.14259. Epub 2019 Dec 30.
249	Association between 11 genetic polymorphisms in folate-metabolising genes and head and neck cancer risk.Eur J Cancer. 2012 Jul;48(10):1525-31. doi: 10.1016/j.ejca.2011.09.025. Epub 2011 Nov 1.
250	Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma. Toxicol Appl Pharmacol. 2017 Sep 15;331:54-61. doi: 10.1016/j.taap.2017.05.008. Epub 2017 May 10.
251	Decreased NK cells in patients with head and neck cancer determined in archival DNA.Clin Cancer Res. 2012 Nov 15;18(22):6147-54. doi: 10.1158/1078-0432.CCR-12-1008. Epub 2012 Sep 26.
252	Decreased expression of GRIM-19 by DNA hypermethylation promotes aerobic glycolysis and cell proliferation in head and neck squamous cell carcinoma.Oncotarget. 2015 Jan 1;6(1):101-15. doi: 10.18632/oncotarget.2684.
253	Vimentin and Non-Muscle Myosin IIA are Members of the Neural Precursor Cell Expressed Developmentally Down-Regulated 9 (NEDD9) Interactome in Head and Neck Squamous Cell Carcinoma Cells.Transl Oncol. 2019 Jan;12(1):49-61. doi: 10.1016/j.tranon.2018.09.006. Epub 2018 Sep 26.
254	WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck.Mol Cancer Res. 2015 Feb;13(2):293-304. doi: 10.1158/1541-7786.MCR-14-0292-T. Epub 2014 Oct 3.
255	Relevance of Neurotrophin Receptors CD271 and TrkC for Prognosis, Migration, and Proliferation in Head and Neck Squamous Cell Carcinoma.Cells. 2019 Sep 28;8(10):1167. doi: 10.3390/cells8101167.
256	EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex.Oncogene. 2016 Sep 8;35(36):4698-707. doi: 10.1038/onc.2016.11. Epub 2016 Feb 15.
257	Nuclear localization of Nm23-H1 in head and neck squamous cell carcinoma is associated with radiation resistance.Cancer. 2011 May 1;117(9):1864-73. doi: 10.1002/cncr.25760. Epub 2010 Nov 18.
258	The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma.PLoS One. 2018 Feb 22;13(2):e0193242. doi: 10.1371/journal.pone.0193242. eCollection 2018.
259	Genomic landscape of human papillomavirus-associated cancers.Clin Cancer Res. 2015 May 1;21(9):2009-19. doi: 10.1158/1078-0432.CCR-14-1101. Epub 2015 Mar 16.
260	Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.Int J Cancer. 2018 Sep 15;143(6):1494-1504. doi: 10.1002/ijc.31534.
261	microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer.Oncotarget. 2016 Feb 16;7(7):8223-39. doi: 10.18632/oncotarget.6972.
262	Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck.Head Neck. 2012 Apr;34(4):513-9. doi: 10.1002/hed.21759. Epub 2011 May 16.
263	Cumulative meta-analysis and trial sequential analysis of correlation between hOGG1 Ser326Cys polymorphism and the risk of head and neck squamous cell carcinoma.Oncotarget. 2018 Jan 6;9(16):13077-13087. doi: 10.18632/oncotarget.24055. eCollection 2018 Feb 27.
264	P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer.Oncotarget. 2017 Jul 25;8(30):48972-48982. doi: 10.18632/oncotarget.16903.
265	High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.J Clin Lab Anal. 2020 Mar;34(3):e23107. doi: 10.1002/jcla.23107. Epub 2019 Nov 29.
266	Regulation of HIF-1 alpha by the proprotein convertases furin and PC7 in human squamous carcinoma cells.Mol Carcinog. 2015 Sep;54(9):698-706. doi: 10.1002/mc.22131. Epub 2014 Jan 16.
267	Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.Head Neck. 2019 Aug;41(8):2484-2491. doi: 10.1002/hed.25713. Epub 2019 Mar 1.
268	The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.Front Immunol. 2019 May 31;10:1206. doi: 10.3389/fimmu.2019.01206. eCollection 2019.
269	A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):564-570. doi: 10.1016/j.ijrobp.2019.09.050. Epub 2019 Oct 31.
270	The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger.Breast Cancer Res Treat. 2010 Jul;122(1):243-9. doi: 10.1007/s10549-009-0682-9. Epub 2009 Dec 24.
271	Role of protein kinase N2 (PKN2) in cigarette smoke-mediated oncogenic transformation of oral cells.J Cell Commun Signal. 2018 Dec;12(4):709-721. doi: 10.1007/s12079-017-0442-2. Epub 2018 Feb 26.
272	Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma.Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1196-202. doi: 10.1016/j.ijrobp.2008.10.070.
273	Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck.Br J Cancer. 2011 May 10;104(10):1641-8. doi: 10.1038/bjc.2011.131. Epub 2011 Apr 19.
274	Coordinated expression of cyclin-dependent kinase-4 and its regulators in human oral tumors.Anticancer Res. 2014 Jul;34(7):3285-92.
275	A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation.Oral Oncol. 2010 Dec;46(12):880-7. doi: 10.1016/j.oraloncology.2010.09.005. Epub 2010 Oct 14.
276	Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma.Auris Nasus Larynx. 2010 Aug;37(4):482-7. doi: 10.1016/j.anl.2009.11.009. Epub 2010 Jan 19.
277	Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck.Carcinogenesis. 2009 Dec;30(12):2053-8. doi: 10.1093/carcin/bgp265.
278	Effects of culture method on response to EGFR therapy in head and neck squamous cell carcinoma cells.Sci Rep. 2019 Aug 28;9(1):12480. doi: 10.1038/s41598-019-48764-3.
279	RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage.Cell Cycle. 2004 Oct;3(10):1285-95. doi: 10.4161/cc.3.10.1155. Epub 2004 Oct 6.
280	Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines.Int J Cancer. 2001 Jun 1;92(5):661-5. doi: 10.1002/1097-0215(20010601)92:5<661::aid-ijc1251>3.0.co;2-o.
281	TNF- promotes c-REL/Np63 interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer.Cancer Res. 2011 Nov 1;71(21):6867-77. doi: 10.1158/0008-5472.CAN-11-2460. Epub 2011 Sep 20.
282	ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.Cancer Cell. 2017 Jan 9;31(1):35-49. doi: 10.1016/j.ccell.2016.12.001. Epub 2016 Dec 29.
283	111 Integrin is Induced in a Subset of Cancer-Associated Fibroblasts in Desmoplastic Tumor Stroma and Mediates In Vitro Cell Migration.Cancers (Basel). 2019 Jun 1;11(6):765. doi: 10.3390/cancers11060765.
284	Intracellular calprotectin (S100A8/A9) controls epithelial differentiation and caspase-mediated cleavage of EGFR in head and neck squamous cell carcinoma.Oral Oncol. 2019 Aug;95:1-10. doi: 10.1016/j.oraloncology.2019.05.027. Epub 2019 Jun 4.
285	Aberrant expression of serum amyloid A in head and neck squamous cell carcinoma.J Oral Pathol Med. 2010 Jan;39(1):41-7. doi: 10.1111/j.1600-0714.2009.00777.x. Epub 2009 Apr 21.
286	CD100-plexin-B1 induces epithelial-mesenchymal transition of head and neck squamous cell carcinoma and promotes metastasis.Cancer Lett. 2019 Jul 28;455:1-13. doi: 10.1016/j.canlet.2019.04.013. Epub 2019 Apr 11.
287	Squamous Cell Carcinoma Antigen-encoding Genes SERPINB3/B4 as Potentially Useful Markers for the Stratification of HNSCC Tumours.Anticancer Res. 2018 Mar;38(3):1343-1352. doi: 10.21873/anticanres.12357.
288	Novel adenoviral gene delivery system targeted against head and neck cancer.Laryngoscope. 2008 Apr;118(4):650-8. doi: 10.1097/MLG.0b013e3181613aba.
289	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity.Clin Cancer Res. 2019 May 15;25(10):3152-3163. doi: 10.1158/1078-0432.CCR-18-2951. Epub 2019 Jan 22.
290	SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.Hum Pathol. 2016 Mar;49:145-55. doi: 10.1016/j.humpath.2015.08.025. Epub 2015 Nov 4.
291	Effects of potentially functional polymorphisms in suppressor of cytokine signaling 3 (SOCS3) on the risk of head and neck squamous cancer.J Oral Pathol Med. 2017 Sep;46(8):598-602. doi: 10.1111/jop.12539. Epub 2017 Jan 23.
292	Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas.Sci Transl Med. 2018 Jun 27;10(447):eaar7223. doi: 10.1126/scitranslmed.aar7223.
293	The Differential Impact of SRC Expression on the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma.Cancers (Basel). 2019 Oct 25;11(11):1644. doi: 10.3390/cancers11111644.
294	Dysregulation of splicing proteins in head and neck squamous cell carcinoma.Cancer Biol Ther. 2016;17(2):219-29. doi: 10.1080/15384047.2016.1139234. Epub 2016 Feb 6.
295	Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.PLoS One. 2015 Mar 3;10(3):e0118588. doi: 10.1371/journal.pone.0118588. eCollection 2015.
296	STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma.Int J Cancer. 2020 Mar 15;146(6):1717-1729. doi: 10.1002/ijc.32781. Epub 2019 Nov 29.
297	Downregulation of LINC00460 decreases STC2 and promotes autophagy of head and neck squamous cell carcinoma by up-regulating microRNA-206.Life Sci. 2019 Aug 15;231:116459. doi: 10.1016/j.lfs.2019.05.015. Epub 2019 May 8.
298	Cytoplasmic DRAK1 overexpressed in head and neck cancers inhibits TGF-1 tumor suppressor activity by binding to Smad3 to interrupt its complex for... Oncogene. 2015 Sep 24;34(39):5037-45.
299	miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma.Oncotarget. 2011 Jan-Feb;2(1-2):29-42. doi: 10.18632/oncotarget.213.
300	Activator protein 2 alpha (AP2alpha) suppresses 42 kDa C/CAAT enhancer binding protein alpha (p42(C/EBPalpha)) in head and neck squamous cell carcinoma.Int J Cancer. 2009 Mar 15;124(6):1285-92. doi: 10.1002/ijc.24087.
301	ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.PLoS One. 2017 Jul 19;12(7):e0181356. doi: 10.1371/journal.pone.0181356. eCollection 2017.
302	TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization.Clin Cancer Res. 2010 Feb 1;16(3):857-66. doi: 10.1158/1078-0432.CCR-09-2604. Epub 2010 Jan 26.
303	The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.Exp Cell Res. 2012 Aug 1;318(13):1564-76. doi: 10.1016/j.yexcr.2012.04.003. Epub 2012 Apr 10.
304	Overexpression of TRIM24 Stimulates Proliferation and Glucose Metabolism of Head and Neck Squamous Cell Carcinoma.Biomed Res Int. 2018 May 10;2018:6142843. doi: 10.1155/2018/6142843. eCollection 2018.
305	Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups.Nat Commun. 2013;4:2873. doi: 10.1038/ncomms3873.
306	Extraribosomal function of metallopanstimulin-1: reducing paxillin in head and neck squamous cell carcinoma and inhibiting tumor growth.Int J Cancer. 2010 Feb 1;126(3):611-9. doi: 10.1002/ijc.24791.
307	Association between dietary folate intake and clinical outcome in head and neck squamous cell carcinoma.Ann Oncol. 2012 Jan;23(1):186-192. doi: 10.1093/annonc/mdr057. Epub 2011 Apr 2.
308	The autophagy associated gene, ULK1, promotes tolerance to chronic and acute hypoxia.Radiother Oncol. 2013 Sep;108(3):529-34. doi: 10.1016/j.radonc.2013.06.015. Epub 2013 Jul 9.
309	Hippo/Mst1 overexpression induces mitochondrial death in head and neck squamous cell carcinoma via activating -catenin/Drp1 pathway.Cell Stress Chaperones. 2019 Jul;24(4):807-816. doi: 10.1007/s12192-019-01008-9. Epub 2019 May 24.
310	Periostin directly and indirectly promotes tumor lymphangiogenesis of head and neck cancer.PLoS One. 2012;7(8):e44488. doi: 10.1371/journal.pone.0044488. Epub 2012 Aug 30.
311	RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma.Cancer Res. 2011 Jul 1;71(13):4598-607. doi: 10.1158/0008-5472.CAN-11-0320. Epub 2011 May 13.
312	ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma.Clin Oral Investig. 2019 Aug;23(8):3319-3329. doi: 10.1007/s00784-018-2751-0. Epub 2018 Nov 29.
313	Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption.Mutat Res. 2008 Oct 30;656(1-2):74-81. doi: 10.1016/j.mrgentox.2008.07.013. Epub 2008 Aug 13.
314	Verteporfin suppresses the proliferation, epithelial-mesenchymal transition and stemness of head and neck squamous carcinoma cells via inhibiting YAP1.J Cancer. 2019 Jul 10;10(18):4196-4207. doi: 10.7150/jca.34145. eCollection 2019.
315	Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.Biochem J. 2019 Dec 19;476(24):3705-3719. doi: 10.1042/BCJ20190591.
316	Sorting Nexin 5 Controls Head and Neck Squamous Cell Carcinoma Progression by Modulating FBW7.J Cancer. 2019 Jun 2;10(13):2942-2952. doi: 10.7150/jca.31055. eCollection 2019.
317	Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1.Oncogene. 2018 Jun;37(25):3384-3398. doi: 10.1038/s41388-017-0110-2. Epub 2018 Jan 18.
318	Taselisib (GDC-0032), a Potent -Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.Clin Cancer Res. 2016 Apr 15;22(8):2009-19. doi: 10.1158/1078-0432.CCR-15-2245. Epub 2015 Nov 20.
319	AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.J Exp Clin Cancer Res. 2019 Jun 10;38(1):245. doi: 10.1186/s13046-019-1256-2.
320	Assessment of cancer stem cell marker expression in primary head and neck squamous cell carcinoma shows prognostic value for aldehyde dehydrogenase (ALDH1A1).Eur J Pharmacol. 2020 Jan 15;867:172837. doi: 10.1016/j.ejphar.2019.172837. Epub 2019 Dec 5.
321	Polymorphisms in metabolizing enzymes and the risk of head and neck squamous cell carcinoma in the Slavic population of the central Europe.Neoplasma. 2010;57(5):415-21. doi: 10.4149/neo_2010_05_415.
322	Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells.PLoS One. 2011;6(11):e27112. doi: 10.1371/journal.pone.0027112. Epub 2011 Nov 8.
323	Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck.Clin Cancer Res. 2007 Jul 15;13(14):4300-5. doi: 10.1158/1078-0432.CCR-07-0469.
324	Identification of Hydroxysteroid (17) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.Cancer Immunol Immunother. 2011 Jul;60(7):919-29. doi: 10.1007/s00262-011-1001-y. Epub 2011 Mar 16.
325	Down-regulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy-induced senescence.Head Neck. 2016 Apr;38 Suppl 1:E934-40. doi: 10.1002/hed.24129. Epub 2015 Jul 18.
326	One-carbon metabolism-related gene polymorphisms and risk of head and neck squamous cell carcinoma: case-control study.Cancer Sci. 2007 Sep;98(9):1439-46. doi: 10.1111/j.1349-7006.2007.00533.x. Epub 2007 Jun 26.
327	GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer.Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):185-91.
328	Downregulation of the circadian Period family genes is positively correlated with poor head and neck squamous cell carcinoma prognosis.Chronobiol Int. 2019 Dec;36(12):1723-1732. doi: 10.1080/07420528.2019.1648486. Epub 2019 Oct 14.
329	Hypomethylation of LINE-1, and not centromeric SAT-, is associated with centromeric instability in head and neck squamous cell carcinoma.Cell Oncol (Dordr). 2012 Aug;35(4):259-67. doi: 10.1007/s13402-012-0085-5. Epub 2012 Jun 21.
330	A case-control study investigating the role of sulfotransferase 1A1 polymorphism in head and neck cancer.J Cancer Res Clin Oncol. 2006 Jul;132(7):466-72. doi: 10.1007/s00432-006-0093-9. Epub 2006 Mar 31.
331	Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.Cancer Gene Ther. 2012 Mar;19(3):181-91. doi: 10.1038/cgt.2011.75. Epub 2011 Nov 11.
332	Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.Oral Oncol. 2017 Nov;74:8-14. doi: 10.1016/j.oraloncology.2017.09.002. Epub 2017 Sep 13.
333	Decreased calpain 6 expression is associated with tumorigenesis and poor prognosis in HNSCC.Oncol Lett. 2017 Apr;13(4):2237-2243. doi: 10.3892/ol.2017.5687. Epub 2017 Feb 7.
334	Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.Oncotarget. 2016 May 3;7(18):26087-98. doi: 10.18632/oncotarget.8317.
335	DDB2 regulates Epithelial-to-Mesenchymal Transition (EMT) in Oral/Head and Neck Squamous Cell Carcinoma.Oncotarget. 2018 Oct 5;9(78):34708-34718. doi: 10.18632/oncotarget.26168. eCollection 2018 Oct 5.
336	Lower DSC1 expression is related to the poor differentiation and prognosis of head and neck squamous cell carcinoma (HNSCC).J Cancer Res Clin Oncol. 2016 Dec;142(12):2461-2468. doi: 10.1007/s00432-016-2233-1. Epub 2016 Sep 6.
337	HPV/E7 induces chemotherapy-mediated tumor suppression by ceramide-dependent mitophagy.EMBO Mol Med. 2017 Aug;9(8):1030-1051. doi: 10.15252/emmm.201607088.
338	Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer.Oral Oncol. 2017 Apr;67:70-76. doi: 10.1016/j.oraloncology.2017.02.003. Epub 2017 Feb 14.
339	In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients.Hum Vaccin Immunother. 2019;15(1):167-178. doi: 10.1080/21645515.2018.1520584. Epub 2018 Oct 12.
340	GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers.Oncogene. 2018 Mar;37(10):1340-1353. doi: 10.1038/s41388-017-0038-6. Epub 2017 Dec 19.
341	Expression profile analysis of head and neck squamous cell carcinomas using data from The Cancer Genome Atlas.Mol Med Rep. 2016 May;13(5):4259-65. doi: 10.3892/mmr.2016.5054. Epub 2016 Mar 28.
342	Survival of Head and Neck Cancer Cells Relies upon LZK Kinase-Mediated Stabilization of Mutant p53.Cancer Res. 2017 Sep 15;77(18):4961-4972. doi: 10.1158/0008-5472.CAN-17-0267. Epub 2017 Jul 31.
343	Clinical and molecular implications of MED15 in head and neck squamous cell carcinoma.Am J Pathol. 2015 Apr;185(4):1114-22. doi: 10.1016/j.ajpath.2014.12.010. Epub 2015 Mar 16.
344	Loss of Mitochondrial Tumor Suppressor Genes Expression Is Associated with Unfavorable Clinical Outcome in Head and Neck Squamous Cell Carcinoma: Data from Retrospective Study.PLoS One. 2016 Jan 19;11(1):e0146948. doi: 10.1371/journal.pone.0146948. eCollection 2016.
345	Tumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma.Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):133-40. doi: 10.1016/j.ijrobp.2007.02.025. Epub 2007 Apr 24.
346	Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.Clin Cancer Res. 2014 Dec 15;20(24):6465-78. doi: 10.1158/1078-0432.CCR-14-0176. Epub 2014 Oct 16.
347	Prognostic significance of NDRG1 expression in oral and oropharyngeal squamous cell carcinoma.Mol Biol Rep. 2012 Dec;39(12):10157-65. doi: 10.1007/s11033-012-1889-0. Epub 2012 Sep 13.
348	Overexpression of neuromedin U is correlated with regional metastasis of head and neck squamous cell carcinoma.Mol Med Rep. 2016 Aug;14(2):1075-82. doi: 10.3892/mmr.2016.5347. Epub 2016 May 27.
349	RPA3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma.J Cell Mol Med. 2017 Nov;21(11):2872-2883. doi: 10.1111/jcmm.13200. Epub 2017 May 30.
350	Trinucleotide repeat length variation in the human ribosomal protein L14 gene (RPL14): localization to 3p21.3 and loss of heterozygosity in lung and oral cancers.Mutat Res. 1998 Nov;406(1):9-23. doi: 10.1016/s1383-5726(98)00006-5.
351	Down-regulation of S100A2 in lymph node metastases of head and neck cancer.Head Neck. 2007 Mar;29(3):236-43. doi: 10.1002/hed.20511.
352	High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma.Mol Med Rep. 2019 Feb;19(2):877-884. doi: 10.3892/mmr.2018.9716. Epub 2018 Dec 3.
353	MAPK1/ERK2 as novel target genes for pain in head and neck cancer patients.BMC Genet. 2016 Feb 13;17:40. doi: 10.1186/s12863-016-0348-7.
354	Smoking-Induced SLPI Expression Hinders HPV Infections Also in Squamous Cell Carcinomas of the Vulva.Transl Oncol. 2019 Jan;12(1):36-42. doi: 10.1016/j.tranon.2018.09.004. Epub 2018 Sep 26.
355	The special stemness functions of Tbx3 in stem cells and cancer development.Semin Cancer Biol. 2019 Aug;57:105-110. doi: 10.1016/j.semcancer.2018.09.010. Epub 2018 Sep 27.
356	ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.Oral Oncol. 2018 Sep;84:95-103. doi: 10.1016/j.oraloncology.2018.07.010. Epub 2018 Jul 27.
357	Identification of SERPINE1, PLAU and ACTA1 as biomarkers of head and neck squamous cell carcinoma based on integrated bioinformatics analysis.Int J Clin Oncol. 2019 Sep;24(9):1030-1041. doi: 10.1007/s10147-019-01435-9. Epub 2019 Apr 1.
358	AFF4 promotes tumorigenesis and tumor-initiation capacity of head and neck squamous cell carcinoma cells by regulating SOX2.Carcinogenesis. 2018 Jul 3;39(7):937-947. doi: 10.1093/carcin/bgy046.
359	Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.Cancer. 2018 Jan 1;124(1):84-94. doi: 10.1002/cncr.31063. Epub 2017 Oct 20.
360	Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells.Oncotarget. 2018 Sep 18;9(73):33832-33843. doi: 10.18632/oncotarget.26112. eCollection 2018 Sep 18.
361	Combined expression and prognostic significance of PPFIA1 and ALG3 in head and neck squamous cell carcinoma.Mol Biol Rep. 2019 Jun;46(3):2693-2701. doi: 10.1007/s11033-019-04712-y. Epub 2019 Feb 25.
362	AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis.Cancer Lett. 2017 Nov 1;408:33-42. doi: 10.1016/j.canlet.2017.08.012. Epub 2017 Aug 18.
363	ATG12 expression quantitative trait loci associated with head and neck squamous cell carcinoma risk in a Chinese Han population.Mol Carcinog. 2018 Aug;57(8):1030-1037. doi: 10.1002/mc.22823. Epub 2018 Apr 24.
364	Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells.Sci Rep. 2014 Aug 20;4:6098. doi: 10.1038/srep06098.
365	Metformin enhances gefitinib efficacy by interfering with interactions between tumor-associated macrophages and head and neck squamous cell carcinoma cells.Cell Oncol (Dordr). 2019 Aug;42(4):459-475. doi: 10.1007/s13402-019-00446-y. Epub 2019 Apr 17.
366	CCL18 promotes the metastasis of squamous cell carcinoma of the head and neck through MTDH-NF-B signalling pathway.J Cell Mol Med. 2019 Apr;23(4):2689-2701. doi: 10.1111/jcmm.14168. Epub 2019 Feb 15.
367	A systematic analysis of immune genes and overall survival in cancer patients.BMC Cancer. 2019 Dec 16;19(1):1225. doi: 10.1186/s12885-019-6414-6.
368	High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: Systematic review and meta-analysis.Head Neck. 2019 May;41(5):1525-1535. doi: 10.1002/hed.25583. Epub 2018 Dec 30.
369	Down-regulation of mitochondrial NADH and cytochrome b gene associated with high tumor stages in head and neck squamous cell carcinoma.Arch Oral Biol. 2019 Mar;99:107-112. doi: 10.1016/j.archoralbio.2019.01.005. Epub 2019 Jan 10.
370	Downregulated cytoplasmic polyadenylation element-binding protein-4 is associated with the carcinogenesis of head and neck squamous cell carcinoma.Oncol Lett. 2018 Mar;15(3):3226-3232. doi: 10.3892/ol.2017.7661. Epub 2017 Dec 20.
371	CUL4B promotes aggressive phenotypes of HNSCC via the activation of the Wnt/-catenin signaling pathway.Cancer Med. 2019 May;8(5):2278-2287. doi: 10.1002/cam4.1960. Epub 2019 Mar 18.
372	Reduced mRNA expression of nucleotide excision repair genes in lymphocytes and risk of squamous cell carcinoma of the head and neck.Carcinogenesis. 2017 May 1;38(5):504-510. doi: 10.1093/carcin/bgx028.
373	DDX3 Activates CBC-eIF3-Mediated Translation of uORF-Containing Oncogenic mRNAs to Promote Metastasis in HNSCC.Cancer Res. 2018 Aug 15;78(16):4512-4523. doi: 10.1158/0008-5472.CAN-18-0282. Epub 2018 Jun 19.
374	Elevated expression of Derlin-1 associates with unfavorable survival time of squamous cell carcinoma of the head and neck and promotes its malignance.J Cancer. 2017 Jul 21;8(12):2336-2345. doi: 10.7150/jca.19411. eCollection 2017.
375	DIAPH1 Is Upregulated and Inhibits Cell Apoptosis through ATR/p53/Caspase-3 Signaling Pathway in Laryngeal Squamous Cell Carcinoma.Dis Markers. 2019 Jan 14;2019:6716472. doi: 10.1155/2019/6716472. eCollection 2019.
376	In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients.Exp Cell Res. 2019 Oct 15;383(2):111508. doi: 10.1016/j.yexcr.2019.111508. Epub 2019 Jul 26.
377	Characterization of Alternative Splicing Events in HPV-Negative Head and Neck Squamous Cell Carcinoma Identifies an Oncogenic DOCK5 Variant.Clin Cancer Res. 2018 Oct 15;24(20):5123-5132. doi: 10.1158/1078-0432.CCR-18-0752. Epub 2018 Jun 26.
378	Effects of the novel polyphenol conjugate DPP-23 on head and neck squamous cell carcinoma cells in vitro.Oncol Lett. 2018 Jul;16(1):654-659. doi: 10.3892/ol.2018.8655. Epub 2018 May 7.
379	Integrative computational analysis of transcriptional and epigenetic alterations implicates DTX1 as a putative tumor suppressor gene in HNSCC.Oncotarget. 2017 Feb 28;8(9):15349-15363. doi: 10.18632/oncotarget.14856.
380	Clinical correlation of opposing molecular signatures in head and neck squamous cell carcinoma.BMC Cancer. 2019 Aug 23;19(1):830. doi: 10.1186/s12885-019-6059-5.
381	ELMO3 expression indicates a poor prognosis in head and neck squamous cell carcinoma - a short report.Cell Oncol (Dordr). 2017 Apr;40(2):193-198. doi: 10.1007/s13402-016-0310-8. Epub 2016 Dec 30.
382	DNA methylation biomarkers for head and neck squamous cell carcinoma.Epigenetics. 2018;13(4):398-409. doi: 10.1080/15592294.2018.1465790. Epub 2018 Aug 10.
383	Silencing of FANCD2 enhances the radiosensitivity of metastatic cervical lymph node-derived head and neck squamous cell carcinoma HSC-4 cells.Int J Oncol. 2017 Apr;50(4):1241-1250. doi: 10.3892/ijo.2017.3902. Epub 2017 Mar 7.
384	Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma.Nat Commun. 2017 Nov 16;8(1):1534. doi: 10.1038/s41467-017-01199-8.
385	FcGBP was upregulated by HPV infection and correlated to longer survival time of HNSCC patients.Oncotarget. 2017 Sep 23;8(49):86503-86514. doi: 10.18632/oncotarget.21220. eCollection 2017 Oct 17.
386	Expression and Prognostic Relevance of GAGE1 and XAGE1 Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma.Curr Mol Med. 2017;17(10):707-717. doi: 10.2174/1566524018666180322162145.
387	Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines.Head Neck. 2017 May;39(5):840-852. doi: 10.1002/hed.24729. Epub 2017 Feb 25.
388	Repression of GPRC5A is associated with activated STAT3, which contributes to tumor progression of head and neck squamous cell carcinoma.Cancer Cell Int. 2017 Mar 2;17:34. doi: 10.1186/s12935-017-0406-x. eCollection 2017.
389	miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.DNA Cell Biol. 2018 Apr;37(4):381-388. doi: 10.1089/dna.2017.4095. Epub 2018 Jan 24.
390	PWP1 Mediates Nutrient-Dependent Growth Control through Nucleolar Regulation of Ribosomal Gene Expression.Dev Cell. 2017 Oct 23;43(2):240-252.e5. doi: 10.1016/j.devcel.2017.09.022.
391	Development and validation of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of head and neck squamous cell carcinoma.Am J Cancer Res. 2019 Oct 1;9(10):2156-2169. eCollection 2019.
392	HOPX functions as a tumour suppressor in head and neck cancer.Sci Rep. 2016 Dec 9;6:38758. doi: 10.1038/srep38758.
393	LINC00355 Promotes Tumor Progression in HNSCC by Hindering MicroRNA-195-Mediated Suppression of HOXA10 Expression.Mol Ther Nucleic Acids. 2020 Mar 6;19:61-71. doi: 10.1016/j.omtn.2019.11.002. Epub 2019 Nov 15.
394	The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma.J Clin Lab Anal. 2019 Jun;33(5):e22873. doi: 10.1002/jcla.22873. Epub 2019 Mar 6.
395	Novel Peptide NIRF Optical Surgical Navigation Agents for HNSCC.Molecules. 2019 Aug 23;24(17):3070. doi: 10.3390/molecules24173070.
396	Association of lnc-IL17RA-11 with increased radiation sensitivity and improved prognosis of HPV-positive HNSCC.J Cell Biochem. 2019 Oct;120(10):17438-17448. doi: 10.1002/jcb.29008. Epub 2019 May 22.
397	Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer.Oncol Rep. 2014 Feb;31(2):1014-20. doi: 10.3892/or.2013.2927. Epub 2013 Dec 16.
398	Jumonji domain-containing protein 6 functions as a marker of head and neck squamous cell carcinoma at advanced stage with no effect on prognosis.Oncol Lett. 2019 Dec;18(6):5843-5852. doi: 10.3892/ol.2019.10938. Epub 2019 Sep 30.
399	A novel read-through transcript JMJD7-PLA2G4B regulates head and neck squamous cell carcinoma cell proliferation and survival.Oncotarget. 2017 Jan 10;8(2):1972-1982. doi: 10.18632/oncotarget.14081.
400	Downregulation of leucinerich?glycoprotein1 expression is associated with the tumorigenesis of head and neck squamous cell carcinoma.Oncol Rep. 2017 Mar;37(3):1503-1510. doi: 10.3892/or.2017.5377. Epub 2017 Jan 17.
401	Endothelial-derived interleukin-6 induces cancer stem cell motility by generating a chemotactic gradient towards blood vessels.Oncotarget. 2017 Nov 1;8(59):100339-100352. doi: 10.18632/oncotarget.22225. eCollection 2017 Nov 21.
402	MAML1 and TWIST1 co-overexpression promote invasion of head and neck squamous cell carcinoma.Asia Pac J Clin Oncol. 2018 Oct;14(5):e434-e441. doi: 10.1111/ajco.12843. Epub 2018 Jan 15.
403	Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.Ann Otol Rhinol Laryngol. 2017 Apr;126(4):334-339. doi: 10.1177/0003489416687309. Epub 2017 Jan 6.
404	p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.Mol Cancer. 2019 Mar 11;18(1):38. doi: 10.1186/s12943-019-0993-3.
405	Methyl-donor depletion of head and neck cancer cells in vitro establishes a less aggressive tumour cell phenotype.Eur J Nutr. 2018 Jun;57(4):1321-1332. doi: 10.1007/s00394-017-1411-5. Epub 2017 Mar 1.
406	DNA methylation-mediated Klotho silencing is an independent prognostic biomarker of head and neck squamous carcinoma.Cancer Manag Res. 2019 Feb 12;11:1383-1390. doi: 10.2147/CMAR.S188415. eCollection 2019.
407	Epstein-Barr virus (EBV)-encoded small RNAs (EBERs) associated with poor prognosis of head and neck carcinomas.Oncotarget. 2017 Apr 18;8(16):27328-27338. doi: 10.18632/oncotarget.16033.
408	Bioinformatic analysis of PFN2 dysregulation and its prognostic value in head and neck squamous carcinoma.Future Oncol. 2018 Feb;14(5):449-459. doi: 10.2217/fon-2017-0348. Epub 2018 Jan 11.
409	POPDC3 is a potential biomarker for prognosis and radioresistance in patients with head and neck squamous cell carcinoma.Oncol Lett. 2019 Nov;18(5):5468-5480. doi: 10.3892/ol.2019.10888. Epub 2019 Sep 19.
410	Oleate-induced PTX3 promotes head and neck squamous cell carcinoma metastasis through the up-regulation of vimentin.Oncotarget. 2017 Jun 20;8(25):41364-41378. doi: 10.18632/oncotarget.17326.
411	QKI, a miR-200 target gene, suppresses epithelial-to-mesenchymal transition and tumor growth.Int J Cancer. 2019 Sep 15;145(6):1585-1595. doi: 10.1002/ijc.32372. Epub 2019 May 14.
412	Rab25 regulates invasion and metastasis in head and neck cancer.Clin Cancer Res. 2013 Mar 15;19(6):1375-88. doi: 10.1158/1078-0432.CCR-12-2858. Epub 2013 Jan 22.
413	Inactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9, MMP2, and IL-6.Clin Cancer Res. 2013 Mar 1;19(5):1169-79. doi: 10.1158/1078-0432.CCR-12-2927. Epub 2013 Jan 24.
414	Mutation screening analysis of the retinoblastoma related gene RB2/p130 in sporadic ovarian cancer and head and neck squamous cell cancer.Mol Pathol. 2002 Jun;55(3):153-5. doi: 10.1136/mp.55.3.153.
415	Resveratrolinduced REG III expression enhances chemo?and radiosensitivity in head and neck cancer in xenograft mice.Oncol Rep. 2019 Jul;42(1):436-442. doi: 10.3892/or.2019.7137. Epub 2019 Apr 25.
416	A six-mRNA prognostic model to predict survival in head and neck squamous cell carcinoma.Cancer Manag Res. 2018 Dec 20;11:131-142. doi: 10.2147/CMAR.S185875. eCollection 2019.
417	Knockdown of LncRNA RHPN1-AS1 Inhibits Cell Migration, Invasion and Proliferation in Head and Neck Squamous Cell Carcinoma.J Cancer. 2019 Jul 5;10(17):4000-4008. doi: 10.7150/jca.29029. eCollection 2019.
418	Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.Clin Cancer Res. 2020 Jan 1;26(1):290-300. doi: 10.1158/1078-0432.CCR-19-1351. Epub 2019 Sep 27.
419	Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.Br J Cancer. 2018 May;118(9):1217-1228. doi: 10.1038/s41416-018-0035-8. Epub 2018 Apr 3.
420	A gene expression profile associated with perineural invasion identifies a subset of HNSCC at risk of post-surgical recurrence.Oral Oncol. 2018 Nov;86:53-60. doi: 10.1016/j.oraloncology.2018.09.005. Epub 2018 Sep 13.
421	Apigenin inhibited hypoxia induced stem cell marker expression in a head and neck squamous cell carcinoma cell line.Arch Oral Biol. 2017 Feb;74:69-74. doi: 10.1016/j.archoralbio.2016.11.010. Epub 2016 Nov 15.
422	Loss of CD169(+) Subcapsular Macrophages during Metastatic Spread of Head and Neck Squamous Cell Carcinoma.Otolaryngol Head Neck Surg. 2019 Jul;161(1):67-73. doi: 10.1177/0194599819829741. Epub 2019 Feb 12.
423	Sentinel Lymph Node-Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model.Mol Cancer Ther. 2019 Aug;18(8):1430-1438. doi: 10.1158/1535-7163.MCT-18-1372. Epub 2019 Jun 6.
424	SMARCD1 is a transcriptional target of specific non-hotspot mutant p53 forms.J Cell Physiol. 2020 May;235(5):4559-4570. doi: 10.1002/jcp.29332. Epub 2019 Oct 21.
425	Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.Mol Cancer Res. 2018 Dec;16(12):1912-1926. doi: 10.1158/1541-7786.MCR-18-0056. Epub 2018 Aug 14.
426	Synthesis and preclinical investigation of (99m)Tc-p-SCN-Bzl-DTPA-cetuximab for targeting EGFR using head and neck squamous cell carcinoma (HNSCC) xenografts.Mol Biol Rep. 2019 Apr;46(2):1675-1682. doi: 10.1007/s11033-019-04616-x. Epub 2019 Jan 24.
427	Regulation of Oncogenic Targets by miR-99a-3p (Passenger Strand of miR-99a-Duplex) in Head and Neck Squamous Cell Carcinoma.Cells. 2019 Nov 28;8(12):1535. doi: 10.3390/cells8121535.
428	STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer.Oral Oncol. 2018 Mar;78:186-193. doi: 10.1016/j.oraloncology.2018.01.019. Epub 2018 Feb 20.
429	TEAD4 overexpression promotes epithelial-mesenchymal transition and associates with aggressiveness and adverse prognosis in head neck squamous cell carcinoma.Cancer Cell Int. 2018 Nov 12;18:178. doi: 10.1186/s12935-018-0675-z. eCollection 2018.
430	Salivary MicroRNAs for Early Detection of Head and Neck Squamous Cell Carcinoma: A Case-Control Study in the High Altitude Mestizo Ecuadorian Population.Biomed Res Int. 2018 Nov 21;2018:9792730. doi: 10.1155/2018/9792730. eCollection 2018.
431	Sox11 promotes head and neck cancer progression via the regulation of SDCCAG8.J Exp Clin Cancer Res. 2019 Mar 29;38(1):138. doi: 10.1186/s13046-019-1146-7.
432	Fumonisin B1 Inhibits Endoplasmic Reticulum Stress Associated-apoptosis After FoscanPDT Combined with C6-Pyridinium Ceramide or Fenretinide.Anticancer Res. 2017 Feb;37(2):455-463. doi: 10.21873/anticanres.11337.
433	Tumor necrosis factor- triggers opposing signals in head and neck squamous cell carcinoma and induces apoptosis via mitochondrial- and non-mitochondrial-dependent pathways.Int J Oncol. 2019 Dec;55(6):1324-1338. doi: 10.3892/ijo.2019.4900. Epub 2019 Oct 17.
434	TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.Cancer. 2017 May 15;123(10):1778-1790. doi: 10.1002/cncr.30570. Epub 2017 Mar 13.
435	Ionizing radiation and TNF-alpha and stimulated expression of alpha1-antichymotrypsin gene in human squamous carcinoma cells.Acta Oncol. 1998;37(5):475-8. doi: 10.1080/028418698430430.
436	A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.Oncogene. 2012 Jun 7;31(23):2888-98. doi: 10.1038/onc.2011.460. Epub 2011 Oct 10.
437	ALKBH overexpression in head and neck cancer: potential target for novel anticancer therapy.Sci Rep. 2019 Sep 13;9(1):13249. doi: 10.1038/s41598-019-49550-x.
438	Clinical significance of melanoma-associated antigen A1-6 expression in sputum of patients with squamous cell carcinoma of the larynx and hypopharynx.Head Neck. 2016 Apr;38 Suppl 1:E736-40. doi: 10.1002/hed.24081. Epub 2015 Jul 18.
439	Evidence for APOBEC3B mutagenesis in multiple human cancers.Nat Genet. 2013 Sep;45(9):977-83. doi: 10.1038/ng.2701. Epub 2013 Jul 14.
440	High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients.Cell Commun Signal. 2014 Mar 12;12:17. doi: 10.1186/1478-811X-12-17.
441	ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells.Biochim Biophys Acta. 2013 Feb;1832(2):365-74. doi: 10.1016/j.bbadis.2012.11.010. Epub 2012 Nov 28.
442	Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck.Cancer. 2012 Jan 15;118(2):485-92. doi: 10.1002/cncr.26222. Epub 2011 Jun 29.
443	-Catulin marks the invasion front of squamous cell carcinoma and is important for tumor cell metastasis.Mol Cancer Res. 2012 Jul;10(7):892-903. doi: 10.1158/1541-7786.MCR-12-0169. Epub 2012 May 30.
444	Actin-related protein 2/3 complex subunit 5 (ARPC5) contributes to cell migration and invasion and is directly regulated by tumor-suppressive microRNA-133a in head and neck squamous cell carcinoma.Int J Oncol. 2012 Jun;40(6):1770-8. doi: 10.3892/ijo.2012.1390. Epub 2012 Feb 29.
445	NFB-p50 as a blood based protein marker for early diagnosis and prognosis of head and neck squamous cell carcinoma.Biochem Biophys Res Commun. 2015 Nov 13;467(2):248-53. doi: 10.1016/j.bbrc.2015.09.181. Epub 2015 Oct 3.
446	Activating transcription factor-2 in survival mechanisms in head and neck carcinoma cells.Head Neck. 2011 Nov;33(11):1586-99. doi: 10.1002/hed.21648. Epub 2010 Dec 28.
447	Impaired mitochondrial protein synthesis in head and neck squamous cell carcinoma.Mitochondrion. 2015 Sep;24:113-21. doi: 10.1016/j.mito.2015.07.123. Epub 2015 Aug 1.
448	Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.Oral Oncol. 2018 May;80:33-39. doi: 10.1016/j.oraloncology.2018.03.005. Epub 2018 Mar 27.
449	CTIP2 expression in human head and neck squamous cell carcinoma is linked to poorly differentiated tumor status.PLoS One. 2009;4(4):e5367. doi: 10.1371/journal.pone.0005367. Epub 2009 Apr 28.
450	Quantitative expression analysis of the apoptosis-related gene, BCL2L12, in head and neck squamous cell carcinoma.J Oral Pathol Med. 2013 Feb;42(2):154-61. doi: 10.1111/j.1600-0714.2012.01190.x. Epub 2012 Jul 2.
451	A novel functional DEC1 promoter polymorphism -249T>C reduces risk of squamous cell carcinoma of the head and neck.Carcinogenesis. 2010 Dec;31(12):2082-90. doi: 10.1093/carcin/bgq198. Epub 2010 Oct 8.
452	C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer.Oncogene. 2018 Oct;37(43):5780-5793. doi: 10.1038/s41388-018-0375-0. Epub 2018 Jun 21.
453	The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma.Oncotarget. 2017 Oct 31;8(59):100280-100287. doi: 10.18632/oncotarget.22213. eCollection 2017 Nov 21.
454	Cyclin L1 (CCNL1) gene alterations in human head and neck squamous cell carcinoma.Br J Cancer. 2006 Apr 10;94(7):1041-4. doi: 10.1038/sj.bjc.6603036.
455	CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.Clin Oral Investig. 2017 Jun;21(5):1503-1508. doi: 10.1007/s00784-016-1911-3. Epub 2016 Jul 21.
456	Prognosis and modulation mechanisms of COMMD6 in human tumours based on expression profiling and comprehensive bioinformatics analysis.Br J Cancer. 2019 Oct;121(8):699-709. doi: 10.1038/s41416-019-0571-x. Epub 2019 Sep 16.
457	CENP-F gene amplification and overexpression in head and neck squamous cell carcinomas.Head Neck. 2001 Feb;23(2):104-12. doi: 10.1002/1097-0347(200102)23:2<104::aid-hed1005>3.0.co;2-0.
458	Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma.Oral Oncol. 2010 Jul;46(7):536-42. doi: 10.1016/j.oraloncology.2010.03.022. Epub 2010 Apr 18.
459	Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas.Mol Cancer Ther. 2007 Feb;6(2):712-22. doi: 10.1158/1535-7163.MCT-06-0558.
460	Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways.FASEB J. 2010 Jan;24(1):296-308. doi: 10.1096/fj.09-135087. Epub 2009 Sep 1.
461	Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1.Cancer Med. 2012 Dec;1(3):295-305. doi: 10.1002/cam4.35. Epub 2012 Oct 2.
462	miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5.Future Oncol. 2016 Dec;12(23):2701-2712. doi: 10.2217/fon-2016-0179. Epub 2016 Aug 11.
463	Genomic assessments of the frequent loss of heterozygosity region on 8p21.3-p22 in head and neck squamous cell carcinoma.Cancer Genet Cytogenet. 2007 Jul 15;176(2):100-6. doi: 10.1016/j.cancergencyto.2007.04.003.
464	Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer.Cancer Med. 2018 Mar;7(3):698-706. doi: 10.1002/cam4.1361. Epub 2018 Feb 14.
465	CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma.Head Neck. 2016 Apr;38 Suppl 1:E1392-403. doi: 10.1002/hed.24232. Epub 2015 Oct 30.
466	PER1 and CLOCK: potential circulating biomarkers for head and neck squamous cell carcinoma.Head Neck. 2014 Jul;36(7):1018-26. doi: 10.1002/hed.23402. Epub 2013 Sep 12.
467	Genetic variations in TERT-CLPTM1L genes and risk of squamous cell carcinoma of the head and neck.Carcinogenesis. 2010 Nov;31(11):1977-81. doi: 10.1093/carcin/bgq179. Epub 2010 Aug 28.
468	Clusterin is a gene-specific target of microRNA-21 in head and neck squamous cell carcinoma. Clin Cancer Res. 2014 Feb 15;20(4):868-77.
469	Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.Cancer Immunol Res. 2020 Feb;8(2):179-191. doi: 10.1158/2326-6066.CIR-19-0394. Epub 2019 Nov 26.
470	Downregulation of COMMD1 by miR-205 promotes a positive feedback loop for amplifying inflammatory- and stemness-associated properties of cancer cells.Cell Death Differ. 2016 May;23(5):841-52. doi: 10.1038/cdd.2015.147. Epub 2015 Nov 20.
471	COX-2 Docking Structural Analysis with Phytochemical Extracts of Rosemary: A Possible Cytotoxicity on Head and Neck Squamous Cell Carcinoma Cell Line (HEp-2).Anticancer Agents Med Chem. 2019;19(12):1473-1480. doi: 10.2174/1871520619666190618121706.
472	Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma.Am J Pathol. 2018 Jan;188(1):72-83. doi: 10.1016/j.ajpath.2017.09.013. Epub 2017 Oct 27.
473	Epigenetic silencing of CRABP2 and MX1 in head and neck tumors.Neoplasia. 2009 Dec;11(12):1329-39. doi: 10.1593/neo.91110.
474	Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck.Cancer. 2002 Jan 15;94(2):393-7. doi: 10.1002/cncr.10231.
475	Clinical Significance of CUB and Sushi Multiple Domains 1 Inactivation in Head and Neck Squamous Cell Carcinoma.Int J Mol Sci. 2018 Dec 12;19(12):3996. doi: 10.3390/ijms19123996.
476	Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis.Br J Cancer. 2004 May 17;90(10):1961-8. doi: 10.1038/sj.bjc.6601830.
477	Frequent alterations of the candidate genes hMLH1, ITGA9 and RBSP3 in early dysplastic lesions of head and neck: clinical and prognostic significance.Cancer Sci. 2010 Jun;101(6):1511-20. doi: 10.1111/j.1349-7006.2010.01551.x. Epub 2010 Feb 4.
478	Cell-cell adhesion genes CTNNA2 and CTNNA3 are tumour suppressors frequently mutated in laryngeal carcinomas.Nat Commun. 2013;4:2531. doi: 10.1038/ncomms3531.
479	Cortactin Phosphorylation by Casein Kinase 2 Regulates Actin-Related Protein 2/3 Complex Activity, Invadopodia Function, and Tumor Cell Invasion.Mol Cancer Res. 2019 Apr;17(4):987-1001. doi: 10.1158/1541-7786.MCR-18-0391. Epub 2019 Jan 4.
480	Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.Oncol Rep. 2010 Feb;23(2):355-63.
481	Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer.Br J Cancer. 2009 Jul 7;101(1):139-44. doi: 10.1038/sj.bjc.6605121.
482	Expression profiles of selected genes in tumors and matched surgical margins in oral cavity cancer: Do we have to pay attention to the molecular analysis of the surgical margins?.Adv Clin Exp Med. 2018 Jun;27(6):833-840. doi: 10.17219/acem/79846.
483	Human -defensin 3 promotes NF-B-mediated CCR7 expression and anti-apoptotic signals in squamous cell carcinoma of the head and neck.Carcinogenesis. 2011 Feb;32(2):168-74. doi: 10.1093/carcin/bgq236. Epub 2010 Nov 11.
484	Expression signature in peripheral blood cells for molecular diagnosis of head and neck squamous cell carcinoma.Oral Dis. 2013 Jul;19(5):452-5. doi: 10.1111/odi.12019. Epub 2012 Oct 3.
485	DLC1 is unlikely to be a primary target for deletions on chromosome arm 8p22 in head and neck squamous cell carcinoma.Cancer Lett. 2004 Jun 25;209(2):207-13. doi: 10.1016/j.canlet.2003.12.018.
486	DLEC1 is not silenced solely by promoter methylation in head and neck squamous cell carcinoma.Gene. 2015 May 25;563(1):83-6. doi: 10.1016/j.gene.2015.03.004. Epub 2015 Mar 6.
487	HSP40 co-chaperone protein Tid1 suppresses metastasis of head and neck cancer by inhibiting Galectin-7-TCF3-MMP9 axis signaling.Theranostics. 2018 Jun 13;8(14):3841-3855. doi: 10.7150/thno.25784. eCollection 2018.
488	A putative oncogenic role for MPP11 in head and neck squamous cell cancer.Cancer Res. 2000 Oct 1;60(19):5529-35.
489	Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma.J Dent Res. 2019 Mar;98(3):268-276. doi: 10.1177/0022034518816947. Epub 2019 Jan 7.
490	Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma.J Oral Pathol Med. 2016 May;45(5):329-37. doi: 10.1111/jop.12372. Epub 2015 Oct 5.
491	Expression microarray analysis reveals alternative splicing of LAMA3 and DST genes in head and neck squamous cell carcinoma.PLoS One. 2014 Mar 27;9(3):e91263. doi: 10.1371/journal.pone.0091263. eCollection 2014.
492	Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma.Mol Cancer. 2014 Jul 15;13:172. doi: 10.1186/1476-4598-13-172.
493	Meta-Analyses of Microarray Datasets Identifies ANO1 and FADD as Prognostic Markers of Head and Neck Cancer.PLoS One. 2016 Jan 25;11(1):e0147409. doi: 10.1371/journal.pone.0147409. eCollection 2016.
494	miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.Mol Cancer Ther. 2015 Oct;14(10):2313-20. doi: 10.1158/1535-7163.MCT-14-1071. Epub 2015 Jul 30.
495	Identification of ESM1 overexpressed in head and neck squamous cell carcinoma.Cancer Cell Int. 2019 May 2;19:118. doi: 10.1186/s12935-019-0833-y. eCollection 2019.
496	Phosphorylated FADD is not prognostic for local control in T1-T2 supraglottic laryngeal carcinoma treated with radiotherapy.Laryngoscope. 2017 Sep;127(9):E301-E307. doi: 10.1002/lary.26563. Epub 2017 Mar 17.
497	Association of FANCC and PTCH1 with the development of early dysplastic lesions of the head and neck.Ann Surg Oncol. 2012 Jul;19 Suppl 3:S528-38. doi: 10.1245/s10434-011-1991-x. Epub 2011 Aug 23.
498	Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.Cancer. 2017 Oct 15;123(20):3943-3954. doi: 10.1002/cncr.30802. Epub 2017 Jul 5.
499	Sendai virus-mediated gene transfer of the c-myc suppressor far-upstream element-binding protein-interacting repressor suppresses head and neck cancer.Gene Ther. 2015 Apr;22(4):297-304. doi: 10.1038/gt.2014.123. Epub 2015 Jan 15.
500	Gold nanoclusters as a contrast agent for image-guided surgery of head and neck tumors.Nanomedicine. 2019 Aug;20:102011. doi: 10.1016/j.nano.2019.04.014. Epub 2019 May 17.
501	DNA ploidy, S-phase fraction and associations with 2-18F-fluoro-deoxy-2-D-glucose positron emission tomography findings before and during therapy of head and neck squamous cell carcinoma.Acta Otolaryngol. 2004 Aug;124(6):712-9. doi: 10.1080/00016480410016973.
502	Visualization of the timing of gene amplification during multistep head and neck tumorigenesis.Cancer Res. 2000 Nov 15;60(22):6496-502.
503	Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays.Oncogene. 2008 Nov 20;27(51):6607-22. doi: 10.1038/onc.2008.251. Epub 2008 Aug 4.
504	Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma.J Hum Genet. 2017 Jan;62(1):113-121. doi: 10.1038/jhg.2016.47. Epub 2016 May 12.
505	CDK2 knockdown enhances head and neck cancer cell radiosensitivity.Int J Radiat Biol. 2013 Jul;89(7):523-31. doi: 10.3109/09553002.2013.782108. Epub 2013 Apr 16.
506	Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma.J Exp Clin Cancer Res. 2014 May 10;33(1):40. doi: 10.1186/1756-9966-33-40.
507	Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.Int J Cancer. 2013 Mar 1;132(5):1042-50. doi: 10.1002/ijc.27763. Epub 2012 Aug 28.
508	Association study of the G-protein beta3 subunit C825T polymorphism with disease progression an overall survival in patients with head and neck squamous cell carcinoma.Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3203-7. doi: 10.1158/1055-9965.EPI-08-0616.
509	Alterations of GPI transamidase subunits in head and neck squamous carcinoma.Mol Cancer. 2007 Nov 21;6:74. doi: 10.1186/1476-4598-6-74.
510	The prognostic value of glycerol-3-phosphate dehydrogenase 1-like expression in head and neck squamous cell carcinoma.Histopathology. 2014 Feb;64(3):348-55. doi: 10.1111/his.12258. Epub 2013 Nov 26.
511	The Proton-Sensing G-Protein Coupled Receptor GPR4 Promotes Angiogenesis in Head and Neck Cancer.PLoS One. 2016 Apr 14;11(4):e0152789. doi: 10.1371/journal.pone.0152789. eCollection 2016.
512	Cytochrome P450 2E1 and head and neck cancer: interaction with genetic and environmental risk factors.Environ Mol Mutagen. 2009 Jul;50(6):473-82. doi: 10.1002/em.20488.
513	Immune-Checkpoint Blockade Opposes CD8(+) T-cell Suppression in Human and Murine Cancer.Cancer Immunol Res. 2019 Mar;7(3):510-525. doi: 10.1158/2326-6066.CIR-18-0054. Epub 2019 Feb 6.
514	Knockdown of HPIP Inhibits the Proliferation and Invasion of Head-and-Neck Squamous Cell Carcinoma Cells by Regulating PI3K/Akt Signaling Pathway.Oncol Res. 2016;24(3):153-60. doi: 10.3727/096504016X14612603423476.
515	FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma.PLoS One. 2012;7(3):e34329. doi: 10.1371/journal.pone.0034329. Epub 2012 Mar 26.
516	Gene-environment interactions of novel variants associated with head and neck cancer.Head Neck. 2012 Aug;34(8):1111-8. doi: 10.1002/hed.21867. Epub 2011 Nov 2.
517	Accumulated SET protein up-regulates and interacts with hnRNPK, increasing its binding to nucleic acids, the Bcl-xS repression, and cellular proliferation.Biochem Biophys Res Commun. 2014 Feb 28;445(1):196-202. doi: 10.1016/j.bbrc.2014.01.175. Epub 2014 Feb 4.
518	Inclusion of hnRNP L Alternative Exon 7 Is Associated with Good Prognosis and Inhibited by Oncogene SRSF3 in Head and Neck Squamous Cell Carcinoma.Biomed Res Int. 2019 Nov 13;2019:9612425. doi: 10.1155/2019/9612425. eCollection 2019.
519	The role of HOXB9 and miR-196a in head and neck squamous cell carcinoma.PLoS One. 2015 Apr 10;10(4):e0122285. doi: 10.1371/journal.pone.0122285. eCollection 2015.
520	HOXC6 is deregulated in human head and neck squamous cell carcinoma and modulates Bcl-2 expression.J Biol Chem. 2012 Oct 12;287(42):35678-35688. doi: 10.1074/jbc.M112.361675. Epub 2012 Aug 15.
521	High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck.PLoS One. 2013;8(2):e56765. doi: 10.1371/journal.pone.0056765. Epub 2013 Feb 28.
522	Tumor-associated antigenic pattern in squamous cell carcinomas of the head and neck--analysed by SEREX.Eur J Cancer. 2013 Mar;49(4):e1-7. doi: 10.1016/j.ejca.2005.09.036. Epub 2006 Jul 11.
523	Regulation of miRNA Biogenesis and Histone Modification by K63-Polyubiquitinated DDX17 Controls Cancer Stem-like Features.Cancer Res. 2019 May 15;79(10):2549-2563. doi: 10.1158/0008-5472.CAN-18-2376. Epub 2019 Mar 15.
524	Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors.Int J Cancer. 2003 Sep 1;106(3):438-45. doi: 10.1002/ijc.11252.
525	PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.Mol Biol Rep. 2019 Jun;46(3):3333-3347. doi: 10.1007/s11033-019-04795-7. Epub 2019 Apr 12.
526	Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma.J Cancer Res Clin Oncol. 2009 May;135(5):703-13. doi: 10.1007/s00432-008-0507-y. Epub 2008 Nov 8.
527	ING3 is required for ATM signaling and DNA repair in response to DNA double strand breaks.Cell Death Differ. 2019 Nov;26(11):2344-2357. doi: 10.1038/s41418-019-0305-x. Epub 2019 Feb 25.
528	Downregulation and translocation of nuclear ING4 is correlated with tumorigenesis and progression of head and neck squamous cell carcinoma.Oral Oncol. 2011 Mar;47(3):217-23. doi: 10.1016/j.oraloncology.2011.01.004.
529	The mutational landscape of head and neck squamous cell carcinoma.Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science.1208130. Epub 2011 Jul 28.
530	Increased nitric oxide levels and iNOS over-expression in oral squamous cell carcinoma.Oral Oncol. 2005 Mar;41(3):261-7. doi: 10.1016/j.oraloncology.2004.09.007.
531	Regulation of ITGA3 by the anti-tumor miR-199 family inhibits cancer cell migration and invasion in head and neck cancer.Cancer Sci. 2017 Aug;108(8):1681-1692. doi: 10.1111/cas.13298. Epub 2017 Jul 4.
532	Insulin-like growth factor binding protein-3 inhibits cell adhesion via suppression of integrin 4 expression.Oncotarget. 2015 Jun 20;6(17):15150-63. doi: 10.18632/oncotarget.3825.
533	KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses.Int J Cancer. 2010 Nov 15;127(10):2351-9. doi: 10.1002/ijc.25248.
534	Telomerase-specific oncolytic adenovirus: antitumor effects on radiation-resistant head and neck squamous cell carcinoma cells.Head Neck. 2014 Mar;36(3):411-8. doi: 10.1002/hed.23309. Epub 2013 Jun 1.
535	Cytokeratins 6 and 16 are frequently expressed in head and neck squamous cell carcinoma cell lines and fresh biopsies.Anticancer Res. 2005 Jul-Aug;25(4):2675-80.
536	Cytokeratin 18 expression in squamous cell carcinoma of the head and neck.Eur Arch Otorhinolaryngol. 1996;253(4-5):227-33. doi: 10.1007/BF00171132.
537	Establishment and characterization of a novel HPV-negative laryngeal squamous cell carcinoma cell line, FD-LSC-1, with missense and nonsense mutations of TP53 in the DNA-binding domain.Cancer Lett. 2014 Jan 1;342(1):92-103. doi: 10.1016/j.canlet.2013.08.041. Epub 2013 Aug 31.
538	Methylationassociated inactivation of LATS1 and its effect on demethylation or overexpression on YAP and cell biological function in human renal cell carcinoma.Int J Oncol. 2014 Dec;45(6):2511-21. doi: 10.3892/ijo.2014.2687. Epub 2014 Sep 30.
539	LDOC1 gene expression in two patients with head and neck squamous cell carcinomas and Parkinson's disease.Tumori. 2012 May-Jun;98(3):86e-88e. doi: 10.1700/1125.12418.
540	LIMD1 is more frequently altered than RB1 in head and neck squamous cell carcinoma: clinical and prognostic implications.Mol Cancer. 2010 Mar 12;9:58. doi: 10.1186/1476-4598-9-58.
541	Lysyl oxidase like-4 monoclonal antibody demonstrates therapeutic effect against head and neck squamous cell carcinoma cells and xenografts.Int J Cancer. 2016 May 15;138(10):2529-38. doi: 10.1002/ijc.29986. Epub 2016 Jan 25.
542	MAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinoma.PLoS One. 2012;7(9):e45534. doi: 10.1371/journal.pone.0045534. Epub 2012 Sep 24.
543	Characterization of squamous cell carcinoma in an organotypic culture via subsurface non-linear optical molecular imaging.Exp Biol Med (Maywood). 2013 Nov 1;238(11):1233-41. doi: 10.1177/1535370213502628. Epub 2013 Oct 1.
544	Identification of an epigenetic profile classifier that is associated with survival in head and neck cancer.Cancer Res. 2012 Jun 1;72(11):2728-37. doi: 10.1158/0008-5472.CAN-11-4121-T. Epub 2012 Apr 16.
545	Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.Cancer Res. 2003 Nov 15;63(22):7936-41.
546	MFAP2 promotes epithelial-mesenchymal transition in gastric cancer cells by activating TGF-/SMAD2/3 signaling pathway.Onco Targets Ther. 2018 Jul 12;11:4001-4017. doi: 10.2147/OTT.S160831. eCollection 2018.
547	Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.Clin Cancer Res. 2005 Apr 1;11(7):2552-60. doi: 10.1158/1078-0432.CCR-04-2146.
548	Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC.Oncotarget. 2015 Oct 20;6(32):33720-32. doi: 10.18632/oncotarget.5606.
549	Smoking and drinking can induce p15 methylation in the upper aerodigestive tract of healthy individuals and patients with head and neck squamous cell carcinoma.Cancer. 2004 Jul 1;101(1):125-32. doi: 10.1002/cncr.20323.
550	Functional repeats (TGYCC)n in the p53-inducible gene 3 (PIG3) promoter and susceptibility to squamous cell carcinoma of the head and neck.Carcinogenesis. 2013 Apr;34(4):812-7. doi: 10.1093/carcin/bgs388. Epub 2012 Dec 14.
551	Tumor suppressive microRNA-133a regulates novel targets: moesin contributes to cancer cell proliferation and invasion in head and neck squamous cell carcinoma.Biochem Biophys Res Commun. 2012 Feb 10;418(2):378-83. doi: 10.1016/j.bbrc.2012.01.030. Epub 2012 Jan 12.
552	Pilot study of mucosal genetic differences in early smokers and nonsmokers.Laryngoscope. 2006 Aug;116(8):1375-9. doi: 10.1097/01.mlg.0000228133.08067.f8.
553	Opposing function of MYBBP1A in proliferation and migration of head and neck squamous cell carcinoma cells.BMC Cancer. 2012 Feb 17;12:72. doi: 10.1186/1471-2407-12-72.
554	Passenger strand of miR-145-3p acts as a tumor-suppressor by targeting MYO1B in head and neck squamous cell carcinoma.Int J Oncol. 2018 Jan;52(1):166-178. doi: 10.3892/ijo.2017.4190. Epub 2017 Nov 6.
555	Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.Oncogene. 2012 Dec 6;31(49):5108-16. doi: 10.1038/onc.2011.660. Epub 2012 Jan 30.
556	Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis.Clin Cancer Res. 2004 Mar 1;10(5):1733-42. doi: 10.1158/1078-0432.ccr-0989-3.
557	Ninein-like protein is overexpressed in head and neck squamous cell carcinoma and contributes to cancer growth and resistance to apoptosis.Oncol Rep. 2009 Oct;22(4):789-98. doi: 10.3892/or_00000501.
558	NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma.Sci Rep. 2019 Aug 2;9(1):11231. doi: 10.1038/s41598-019-47755-8.
559	WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.Sci Rep. 2017 Jan 19;7:40664. doi: 10.1038/srep40664.
560	Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discov. 2013 Jan;3(1):96-111. doi: 10.1158/2159-8290.CD-12-0031. Epub 2012 Nov 2.
561	Axon guidance molecule semaphorin3A is a novel tumor suppressor in head and neck squamous cell carcinoma.Oncotarget. 2016 Feb 2;7(5):6048-62. doi: 10.18632/oncotarget.6831.
562	The prognostic utility of haptoglobin genotypes in squamous cell carcinoma of the head and neck.Clin Chem Lab Med. 2009;47(10):1277-83. doi: 10.1515/CCLM.2009.275.
563	Cox-2 and IL-10 polymorphisms and association with squamous cell carcinoma of the head and neck in a Korean sample.J Korean Med Sci. 2010 Jul;25(7):1024-8. doi: 10.3346/jkms.2010.25.7.1024. Epub 2010 Jun 17.
564	Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.Sci Rep. 2016 Dec 12;6:38792. doi: 10.1038/srep38792.
565	Decreased expression of cell adhesion genes in cancer stem-like cells isolated from primary oral squamous cell carcinomas.Tumour Biol. 2018 May;40(5):1010428318780859. doi: 10.1177/1010428318780859.
566	Human papillomavirus-stratified analysis of the prognostic role of miR-21 in oral cavity and oropharyngeal squamous cell carcinoma.Pathol Int. 2014 Oct;64(10):499-507. doi: 10.1111/pin.12201. Epub 2014 Sep 19.
567	Correlation between podoplanin expression and extracapsular spread in squamous cell carcinoma of the oral cavity using subjective immunoreactivity scores and semiquantitative image analysis.Head Neck. 2017 Jan;39(1):98-108. doi: 10.1002/hed.24537. Epub 2016 Jul 20.
568	Altered expression of circadian clock genes in head and neck squamous cell carcinoma.Tumour Biol. 2012 Feb;33(1):149-55. doi: 10.1007/s13277-011-0258-2. Epub 2011 Nov 15.
569	Inactivation of 9q22.3 tumor suppressor genes predict outcome for patients with head and neck squamous cell carcinoma.Anticancer Res. 2013 Mar;33(3):1215-20.
570	Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.PLoS One. 2017 Jun 15;12(6):e0179412. doi: 10.1371/journal.pone.0179412. eCollection 2017.
571	Identification and characterization of dysregulated P-element induced wimpy testis-interacting RNAs in head and neck squamous cell carcinoma.Oncol Lett. 2019 Mar;17(3):2615-2622. doi: 10.3892/ol.2019.9913. Epub 2019 Jan 9.
572	Loss of expression of ZAC/LOT1 in squamous cell carcinomas of head and neck.Head Neck. 2004 Apr;26(4):338-44. doi: 10.1002/hed.10386.
573	Association between novel PLCE1 variants identified in published esophageal cancer genome-wide association studies and risk of squamous cell carcinoma of the head and neck.BMC Cancer. 2011 Jun 20;11:258. doi: 10.1186/1471-2407-11-258.
574	Plectin promotes migration and invasion of cancer cells and is a novel prognostic marker for head and neck squamous cell carcinoma.J Proteomics. 2012 Mar 16;75(6):1803-15. doi: 10.1016/j.jprot.2011.12.018. Epub 2011 Dec 30.
575	Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment.PLoS One. 2019 Jul 5;14(7):e0219398. doi: 10.1371/journal.pone.0219398. eCollection 2019.
576	S100A8/A9 (calprotectin) negatively regulates G2/M cell cycle progression and growth of squamous cell carcinoma.PLoS One. 2013 Jul 9;8(7):e69395. doi: 10.1371/journal.pone.0069395. Print 2013.
577	Dysregulated cholinergic network as a novel biomarker of poor prognostic in patients with head and neck squamous cell carcinoma.BMC Cancer. 2015 May 10;15:385. doi: 10.1186/s12885-015-1402-y.
578	SET protein accumulation prevents cell death in head and neck squamous cell carcinoma through regulation of redox state and autophagy.Biochim Biophys Acta Mol Cell Res. 2019 Apr;1866(4):623-637. doi: 10.1016/j.bbamcr.2019.01.005. Epub 2019 Jan 16.
579	AlloDriver: a method for the identification and analysis of cancer driver targets.Nucleic Acids Res. 2019 Jul 2;47(W1):W315-W321. doi: 10.1093/nar/gkz350.
580	Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.Oncogene. 2016 Mar 3;35(9):1163-9. doi: 10.1038/onc.2015.171. Epub 2015 May 18.
581	PTTG and PBF Functionally Interact with p53 and Predict Overall Survival in Head and Neck Cancer.Cancer Res. 2018 Oct 15;78(20):5863-5876. doi: 10.1158/0008-5472.CAN-18-0855. Epub 2018 Aug 28.
582	RAR beta2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age.Oncol Rep. 2007 Jul;18(1):105-12.
583	RacGAP1 Is a Novel Downstream Effector of E2F7-Dependent Resistance to Doxorubicin and Is Prognostic for Overall Survival in Squamous Cell Carcinoma.Mol Cancer Ther. 2015 Aug;14(8):1939-50. doi: 10.1158/1535-7163.MCT-15-0076. Epub 2015 May 27.
584	The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas.Cancers (Basel). 2019 Sep 11;11(9):1347. doi: 10.3390/cancers11091347.
585	Head and neck squamous cell carcinoma targeted chemosensitization.Otolaryngol Head Neck Surg. 2009 Aug;141(2):177-83. doi: 10.1016/j.otohns.2009.04.024.
586	RAD51C--a new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC).Oral Oncol. 2014 Mar;50(3):196-9. doi: 10.1016/j.oraloncology.2013.11.007. Epub 2013 Dec 6.
587	The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma.Oncogene. 2011 Oct 20;30(42):4339-49. doi: 10.1038/onc.2011.141. Epub 2011 May 2.
588	Aberrant Methylation of RASSF1A Closely Associated with HNSCC, a Meta-Analysis.Sci Rep. 2016 Feb 9;6:20756. doi: 10.1038/srep20756.
589	Functional single nucleotide polymorphisms of the RASSF3 gene and susceptibility to squamous cell carcinoma of the head and neck.Eur J Cancer. 2014 Feb;50(3):582-92. doi: 10.1016/j.ejca.2013.11.009. Epub 2013 Nov 29.
590	Transcriptional regulation of retinoic acid responsive genes by cellular retinoic acid binding protein-II modulates RA mediated tumor cell proliferation and invasion.Anticancer Res. 1998 Jan-Feb;18(1A):217-24.
591	Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.Cancer Sci. 2012 Jul;103(7):1259-66. doi: 10.1111/j.1349-7006.2012.02301.x. Epub 2012 May 25.
592	Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms: Association with poor prognosis in head and neck cancer.Head Neck. 2015 May;37(5):727-34. doi: 10.1002/hed.23663. Epub 2014 Jun 18.
593	High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers.Cancer Sci. 2009 May;100(5):866-72. doi: 10.1111/j.1349-7006.2009.01122.x.
594	Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.Sci Rep. 2016 Jan 21;6:19552. doi: 10.1038/srep19552.
595	The atypical Rho GTPase RhoBTB2 is required for expression of the chemokine CXCL14 in normal and cancerous epithelial cells.Oncogene. 2008 Nov 20;27(54):6856-65. doi: 10.1038/onc.2008.317. Epub 2008 Sep 1.
596	RhoC expression and head and neck cancer metastasis.Mol Cancer Res. 2009 Nov;7(11):1771-80. doi: 10.1158/1541-7786.MCR-08-0512. Epub 2009 Oct 27.
597	The p53-reactivating small molecule RITA induces senescence in head and neck cancer cells.PLoS One. 2014 Aug 13;9(8):e104821. doi: 10.1371/journal.pone.0104821. eCollection 2014.
598	Reference gene selection for head and neck squamous cell carcinoma gene expression studies.BMC Mol Biol. 2009 Aug 3;10:78. doi: 10.1186/1471-2199-10-78.
599	Investigation of the association of hRRM1 and p53R2 gene polymorphisms in head and neck squamous cell carcinomas.Med Oncol. 2014 Jul;31(7):12. doi: 10.1007/s12032-014-0012-x. Epub 2014 May 27.
600	Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer.Int J Cancer. 2019 Dec 15;145(12):3299-3310. doi: 10.1002/ijc.32481. Epub 2019 Jun 19.
601	Nuclear S100A7 is associated with poor prognosis in head and neck cancer.PLoS One. 2010 Aug 3;5(8):e11939. doi: 10.1371/journal.pone.0011939.
602	SATB2 augments Np63 in head and neck squamous cell carcinoma.EMBO Rep. 2010 Oct;11(10):777-83. doi: 10.1038/embor.2010.125. Epub 2010 Sep 10.
603	DNA microarray reveals ZNF195 and SBF1 are potential biomarkers for gemcitabine sensitivity in head and neck squamous cell carcinoma cell lines.Int J Clin Exp Pathol. 2014 Mar 15;7(4):1514-23. eCollection 2014.
604	Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers: results of RTOG 91-08.Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):661-71. doi: 10.1016/0360-3016(94)90552-5.
605	Syntenin-1 is a promoter and prognostic marker of head and neck squamous cell carcinoma invasion and metastasis.Oncotarget. 2016 Dec 13;7(50):82634-82647. doi: 10.18632/oncotarget.13020.
606	Expression of 3q oncogene SEC62 in atypical fibroxanthoma-immunohistochemical analysis of 41 cases and correlation with clinical, viral and histopathologic features.Oncol Lett. 2019 Feb;17(2):1768-1776. doi: 10.3892/ol.2018.9767. Epub 2018 Nov 27.
607	MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase.J Steroid Biochem Mol Biol. 2013 Nov;138:427-34. doi: 10.1016/j.jsbmb.2013.09.002. Epub 2013 Sep 14.
608	Downregulation of SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome.Int J Cancer. 2009 Oct 1;125(7):1542-50. doi: 10.1002/ijc.24507.
609	SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.Mol Carcinog. 2014 Oct;53(10):777-86. doi: 10.1002/mc.22033. Epub 2013 May 9.
610	Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer.Tumour Biol. 2018 Apr;40(4):1010428318772202. doi: 10.1177/1010428318772202.
611	Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma.Cancer. 2011 Jun 15;117(12):2677-89. doi: 10.1002/cncr.25859. Epub 2011 Jan 10.
612	SNP rs1049430 in the 3'-UTR of SH3GL2 regulates its expression: Clinical and prognostic implications in head and neck squamous cell carcinoma.Biochim Biophys Acta. 2015 May;1852(5):1059-67. doi: 10.1016/j.bbadis.2015.02.009. Epub 2015 Feb 26.
613	A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway.Neoplasia. 2010 Oct;12(10):789-96. doi: 10.1593/neo.10396.
614	The potential of SIRT6 and SIRT7 as circulating markers for head and neck squamous cell carcinoma.Anticancer Res. 2014 Dec;34(12):7137-43.
615	Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas.Mol Carcinog. 2019 May;58(5):666-673. doi: 10.1002/mc.22958. Epub 2019 Jan 16.
616	Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk.Carcinogenesis. 2013 May;34(5):1012-7. doi: 10.1093/carcin/bgt008. Epub 2013 Jan 15.
617	Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival.Clin Cancer Res. 2012 Mar 1;18(5):1257-67. doi: 10.1158/1078-0432.CCR-11-2058. Epub 2012 Jan 13.
618	Regulation of submaxillary gland androgen-regulated protein 3A via estrogen receptor 2 in radioresistant head and neck squamous cell carcinoma cells.J Exp Clin Cancer Res. 2017 Feb 6;36(1):25. doi: 10.1186/s13046-017-0496-2.
619	Inter-observer and segmentation method variability of textural analysis in pre-therapeutic FDG PET/CT in head and neck cancer.PLoS One. 2019 Mar 28;14(3):e0214299. doi: 10.1371/journal.pone.0214299. eCollection 2019.
620	SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma.Mol Cancer. 2014 Dec 3;13:260. doi: 10.1186/1476-4598-13-260.
621	Np63/SRC/Slug Signaling Axis Promotes Epithelial-to-Mesenchymal Transition in Squamous Cancers.Clin Cancer Res. 2018 Aug 15;24(16):3917-3927. doi: 10.1158/1078-0432.CCR-17-3775. Epub 2018 May 8.
622	A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).Mol Oncol. 2018 Dec;12(12):2085-2101. doi: 10.1002/1878-0261.12388. Epub 2018 Oct 26.
623	p38 MAPK mediates epithelial-mesenchymal transition by regulating p38IP and Snail in head and neck squamous cell carcinoma.Oral Oncol. 2016 Sep;60:81-9. doi: 10.1016/j.oraloncology.2016.06.010. Epub 2016 Jul 15.
624	Genetic variation in Transaldolase 1 and risk of squamous cell carcinoma of the head and neck.Cancer Detect Prev. 2008;32(3):200-8. doi: 10.1016/j.cdp.2008.08.008. Epub 2008 Sep 20.
625	Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma.Cell Oncol (Dordr). 2013 Jun;36(3):213-24. doi: 10.1007/s13402-013-0129-5. Epub 2013 Mar 26.
626	Decreased mitochondrial copy numbers in oral squamous cell carcinoma.Head Neck. 2016 Aug;38(8):1170-5. doi: 10.1002/hed.24194. Epub 2016 Apr 15.
627	Gene expression profiles in HPV-infected head and neck cancer.J Pathol. 2007 Nov;213(3):283-93. doi: 10.1002/path.2227.
628	Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma.Oncotarget. 2016 Mar 8;7(10):11651-63. doi: 10.18632/oncotarget.7309.
629	Carboxyl-Terminal Modulator Protein Positively Acts as an Oncogenic Driver in Head and Neck Squamous Cell Carcinoma via Regulating Akt phosphorylation.Sci Rep. 2016 Jun 22;6:28503. doi: 10.1038/srep28503.
630	Impact of HPV infection on gene expression and methylation in oral cancer patients.J Med Microbiol. 2019 Mar;68(3):440-445. doi: 10.1099/jmm.0.000898. Epub 2019 Jan 9.
631	Variants of EVER1 and EVER2 (TMC6 and TMC8) and human papillomavirus status in patients with mucosal squamous cell carcinoma of the head and neck.Cancer Causes Control. 2016 Jun;27(6):809-15. doi: 10.1007/s10552-016-0749-y. Epub 2016 Apr 20.
632	Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin.Cell Death Dis. 2019 Dec 4;10(12):919. doi: 10.1038/s41419-019-2088-x.
633	Human DESC1 serine protease confers tumorigenic properties to MDCK cells and it is upregulated in tumours of different origin.Br J Cancer. 2007 Jul 16;97(2):201-9. doi: 10.1038/sj.bjc.6603856. Epub 2007 Jun 19.
634	A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck.Carcinogenesis. 2011 Nov;32(11):1668-74. doi: 10.1093/carcin/bgr209. Epub 2011 Sep 20.
635	Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response.Oral Oncol. 1997 May;33(3):197-203. doi: 10.1016/s0964-1955(96)00065-6.
636	TRAF4 is potently induced by TAp63 isoforms and localised according to differentiation in SCCHN.Cancer Biol Ther. 2007 Dec;6(12):1986-90. doi: 10.4161/cbt.6.12.5002. Epub 2007 Sep 8.
637	Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.Mol Cancer Res. 2014 Apr;12(4):571-82. doi: 10.1158/1541-7786.MCR-13-0396. Epub 2014 Jan 14.
638	TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.Nat Commun. 2014 Jul 31;5:4527. doi: 10.1038/ncomms5527.
639	Midkine promotes tetraspanin-integrin interaction and induces FAK-Stat1alpha pathway contributing to migration/invasiveness of human head and neck squamous cell carcinoma cells.Biochem Biophys Res Commun. 2008 Dec 12;377(2):474-478. doi: 10.1016/j.bbrc.2008.09.138. Epub 2008 Oct 11.
640	POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer.Oncotarget. 2014 Sep 30;5(18):8803-15. doi: 10.18632/oncotarget.2492.
641	Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling.Mol Cancer Res. 2019 Jun;17(6):1279-1293. doi: 10.1158/1541-7786.MCR-18-1355. Epub 2019 Mar 25.